+UU)BF=IO^!H=1>0A//4$%L3/'32QO]Z" Z01'
M#;YR!N_B?,CHJ>[!XM"#?;))!N[(4?+HO=MCY15YGF<7'W)\3K(/LVG;K/MJ
MY_DL.YN=BMDDFTYGXN'-PDLXA/2=9?G%1$RS\6PL)M-I-IN>B_S\(IN>?8 <
M%$FJYR7U^*)FGWP<.R].O+*C5FKAFU JFX^'YV0 #E'^Y2%^BJ_G7 O ONHHO-TJ"
MSK0 SU<.G&F_T ;=ST?7OP-02P,$% @ ]H*L5$HLE45F P I@< !D
M !X;"]W;W)K&ULE57;;N,V$/V5@1JTNP!K76W)
MJ6T@SF[0/FP1K)/M0]$'6AI;A"722U+KI%_?H20K-\= 'R1QR)ES9@[%X>R@
M],Z4B!8>ZDJ:N5=:N[_T?9.76',S4GN4M+)1NN:63+WUS5XC+]J@NO*C()CX
M-1?26\S:N5N]F*G&5D+BK0;3U#77CTNLU&'NA=YQXJO8EM9-^(O9GF]QA?9^
M?ZO)\@>40M0HC5 2-&[FWE5XN4R^OP3>#!/!N#JV2MU,X9?Q1S+W )886Y
M=0BAN4%;:AM-R0GI-F5E-:T*BK.+/Y5%2.!7N.:F9.T;
M/G]OQ ]>H;0&N"S@"]<[M'Q=(:PP;[2P LW,MT3O0/R\IUIV5-$[5#%\4=*6
M!C[+ HN7\3ZE/>0>'7-?1F 4KRRW63HDS^,F G[3XR3OXIR5F[VL,?]_A@X5EI?+=/Z<$/\^7C/I=S1TE
MOMK5^HG1/#'>E0@;5=%9%7(+@ER/YQ74!BRM7JMZS^7C+Z:#=5!O\3EL&GS"'.LUZN-,V,DC)!TUN6M3D,8*V[@C;. "0A9'$Q:F
M&8WC@,5!QH)T[/XL?.Q+@DTC"P-C%B03-@E22%D0C%F2Q2[W&G6[LWN^=[0L
MF4[9.!G#SS]E41C]!G?*TNH%3%F61BR. T>4LCB,V7B<_2]]3BO<:?-2ATNX
MJI6VXE\D,96Q<"^IPU:MO:7.:IY/5,H8PKGA0L,W7C7XMBS2:PL?.99*2EN,8[D>K$5AB, T5LE9.OY@%5',VF0[A'QRFBZ6E
M(*' 8% KBE@:$?0D?$F7$ >I]K%SF61NQ^)6Q%XF*$0!4MFW?\+HE4:O[3;*
M/;;4B*\73TV.3IUA_UGO)!&W[0U!_[9JI.W:Z# [7$)77>]]Z"[6Z$SK-JWG7BM+/7U=EC218K:.=#Z1E$'Z@U',%S-B_\ 4$L#
M!!0 ( /:"K%0R[0H+( 4 +X+ 9 >&PO=V]R:W-H965TRW//O9"7&V,?7(GHX:E2VEWU2N_KV6#@\A(K
MX?JF1DTG*V,KX6EIUP-76Q1%4*K4($O3R: 24O?FEV'OBYU?FL8KJ?&+!==4
ME;#;&U1F<]4[Z^TVOLIUZ7EC,+^LQ1H7Z+_57RRM!GLKA:Q0.VDT6%Q=]:[/
M9C.&^J5ID05%+'7_'4\M!1F*8O*&2M0A9P1T_&X\PAG?P44@+WX5J$,P*/DHM="Z%@L_:>=M0&KR[
M''CRR'J#O+5^$ZUG+U@?PIW1OG3PJRZP.-8?$-(]W&P']R9[U>"=L'T8GB60
MI5GVBKWA/OQAL#=\)7P'WG0"7GCA\42\1_9'>_NC8'_T@OT.JQ^DRY5QC26'
M?]WCDX<;9?*'OT^Q^JI1[M.9JT6.5SUJ1(?V$7OS-]E*O8=W(*&/Q1R.9Y!"2 -U42P))C#BYUG)%JMK#
M/TVQCHQ0N)4HL _712'9IU!JF\#JB*C&$1D\1$ ;3>PTUK)3F@C4D5C2G.U"I2A7
M^[S+0][[\ %ICA=LC&QPWHE@=DX:O&IQ"UWLDRG1)6362M,XB/%Q1CSFI98_
M&HS2I-A4-9_0FNP%IC8E)1J=ES0VV>4!81_NR5LNK-WR@:@X1,+I$=
MH%M#].GM+S]-L[/S]^YT6 DM$5>:AJ*QY8KP45X?0@OZXULN@9_T[+LYC[LC7$=/W!_24:477WJ[1
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M\#*"=7Z13$?3KB:7^=$X/%7;;>K!;PQ!W,*IBW[0>5,1-^OP&ULE55-;]LX$/TK Z%'-;(^;%F!;2!.
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MGKGGXUK:\ O' 3N+@/?6Z6X()@6=4*QKJ\%\"LB$@"[I/B8+*.^;89F7T
M$8Q'$YLWPE%#-(D3RC?EP1G:%13G-I^T0UC 6[CAW/18P[LGZK=%"TS5\)=K
MT796OLTN$GYDY@KR-(9LEF47^/*Q$GG@RR]4PH+3\%XHIKA@$AX<3MV'.Z08[>C/(,G';4<
MV+,AVB#E;!N4@6O4^0;RJHJ714G6LJSBJIP0&-V@]7.'+DA$Z++%XLEI 5
M95S.BA')J:RD4H)U?>T/./*G<5%F<9I64"X7\;RLAB*F61E7506+>5SE<_BB
M'46_ 8+Z%'E.=AI7RUF<+BMXZ=HED\?>H=F'D>8K2Y?K].Y'[S@U;T[#XA?\
M-'*IHGNA+$AL*'1V5:'LVP\ G&
M_Y+-OU!+ P04 " #V@JQ4.2I:93$% #*# &0 'AL+W=O+BR0J)&4G_WYWE.0X71PL!>)8(GGOW;T['NGCK=(W)D>T<%<6E3D9
MY-;6;X=#D^98"N.K&BN:62E="DNO>CTTM4:1.:.R&$9!D Q+(:O!_-B-7>KY
ML6IL(2N\U&":LA3Z_@P+M3T9A(-^X$JN<\L#P_EQ+=9XC?:/^E+3VW"'DLD2
M*R-5!1I7)X/3\.U9S.O=@C\E;LW>,W D2Z5N^.5#=C((V"$L,+6,(.AK@PLL
M"@8B-VX[S,&.D@WWGWOT=RYVBF4I#"Y4\4UF-C\93 >0X4HTA;U2V_?8Q3-F
MO%05QOV';;MVG P@;8Q596=,'I2R:K_%7:?#GL$T.& 0=0:1\[LE"ROF
MQUIM0?-J0N,'%ZJS)N=DQ4FYMIIF)=G9^6=E$2;P*UQ;E=[DJLA0FU=P<=M(
M>P^BRF"ARI+D<_/P36@M*FN.AY;(&6*8=D1G+5%T@&@$GU1E!?PDM ^CT(,HB*)G\$8[)48.;_2,$@:L@G>R$E4J14$Q"XM4
M@=_'^P@_WN''#C\^@/^DP$[^\LG!6T].^G-'Z6@C?P6U.+
M%$\&M$,-Z@T.YA/_A;F%2RTW%#A<%@3%X8-:P35J2?HL:!97J#5FG=F7"B@5
M:0[AM,V%!V$0_ Q'8R\( A^^YOA@O$!MY4JF#%]KM9$9:YX+ZX$@3]:@;(Z:
M1F2U-AZ\EF\ !6&;7) ZS[DA#:2JVC#^LD"0%64R\(.H-35L2] <<2VJ^U>\
MVL5NV-JC_N(4JRP1@^B@7.>IM4P=]5$T]H, :O+/87K4R9;_4'?AHDF)F%H@
M&V:2^XWS_O^[3_W26$H)T[M0FLK2)/NZD!9>[VG*1**FX51P2O$NS46U1BBD<>2Z*="\<3K_F-"Y,,X1S:W;95$8
M"Z&74)HK9;FT3RG]Q5YI/[UCSAOM$D>/N!%%(]R)0VY@N]>)&JL9P]4F5T,Z@0*A0ME7?05H,
MIQ1_XFG K8Q3TTC#.QA^EV(I*:VN^MH>TO=S#[[LY>G*
MI9WEO$.=2H/=IMQM1;BXJZ5NQ'""=>$D^YYU 3FS'A*$C\
M('9VG*ASI-Z\) &(.7X1\V>UZ2T/TL=>E%"XX<0?AYVK+V39\^\@2T(L,<48
M^LG4A1C[L^B[R#C6CTV%_#;^ 86CX !Y&'HQX1\E8S\9=^7WXQR2VC-9Z-[@
MH51C;S;C1%*Y[$O_0J)WN-1]H84'(AI1D<:4M23V@^DCBX2B#;WI+.P[%4/:
M7"/^9]\]==,9[MTO2]1K=XON#JGVJKD;W5W43]O[Z
&ULE5?;;N,V$/V5@9L6":#(EF392IH$B/?6%MC=(-GL/A1]8"3:)B*)7I*R
MDWY]SU#R)7?TQ::HN9Z9.:1.5MKNN-2S6;.][HGYTLQ$Q>27>]N#!XZF^L%*J2M56Z)B.GI[WSZ'@R
M9'DO\%W)E=U9$V=RH_4M/_Q9G/8&') L9>[8@L#?4KZ39KDOK?VG5R@[3
M'N6-=;KJE!%!I>KV7]QU..PH9(,7%.).(?9QMXY\E.^%$V:6/M2%+![J]Q'>)L9X'>,D?M7@9V%"2J* XD$2<
M>'O)*SE;<7^<&-_Z.T/7[!_-1=&'DX\E!?BGLW2
MN3&BGGD7]/>=H4@+P?YZ#]U7K/*7'=B%R>=K#&%IIEK)WEH5= 2=/"@C4
MHI2^S66[^$O4#::/(GHOCG\PW\P=8<.Q'U/48S
MUP:5)KO30OEN!/*.UY)430Z*4UV""U0]V[S(@?Y,&X6RZ"DI9ZFI15,H!TNJ
M=M*H"A9KJTM5".==K>O%"J HXSU9V#;>!W:4+BRT"\76BV/$;*1\T)N/Y1F07848Y$DP6 PH$^RAN/22XH"TZFLXT"6P#HZ
M"N+DB*)A%L39@+YI!\$W$=JC>)P%41)A%651J_H ,B=N2MEQJ/J7^QBO/;&*#3;%$LC.)
M6*7)%8)=&)5[I,ERQS^5-)*/!8X:Q0,RN6L 0JFFDO;1"_? V1[0^6QFY QA
M,CZ$8)6PJ.TA%]E]8CA<[AVN==
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M!Y!+R[XW0>+AW'\NV5&103K_F[/&M__D/?N0^]E
M?7ZT7V'+-$@'+1.%XVS-/?O1 >TG\1A<&*=A.GB#"],@ROS9!]X^ S/D!Y@/>OZP2-^
M']/0[_L[5N9)FYC\0N)6:VK6WZ,WNYAODO+UZ;\7;#QBXPRQ8*N44JH-P
MC"N_:3\*V@>G%_XB?J,=KO5^.<=WE#0L@/=3C8MI]\ .-E]F9_\!4$L#!!0
M ( /:"K%1SF]I7V@0 ($* 9 >&PO=V]R:W-H965T;)W_$2KF2 ^UL>$RJV)LWHY&(:^X5F'H&K;X
M4CI?JXBM7X]"XUD52:DVH^EX_'I4*VVSQ462+?WBPK71:,M+3Z&M:^4?K]FX
M[64VR9X$=WI=11&,%A>-6O,]QS^:I<=NM$,I=,TV:&?)7L_E?#KP
M7?,V'*Q)/%DY]T,V'XO+;"R$V' >!4'A9\,W;(P @<8_/6:V,RF*A^LG]/?)
M=_BR4H%OG/E3%[&ZS,XR*KA4K8EW;ON!>W].!2]W)J3_M.W.GLXSRML07=TK
M@T&M;?>K'OHX'"B;3X\"?E9^2+/)@*;CZ?0(WFSG^"SAS8XX
M'B@Z>J^M@I/*T'U4D5,$CN#/=_CSA#]_ ?]H/.E6A]RXT'JFO[[Q0Z1KX_(?
M?_\JSD?-2,^^#8W*^3)#4P;V&\X6Y\/CZ:2O9:ESIGM1I$^,JCY0H&]5VC;*
M/E*E H7*^4B1?4UJ[;D+D82NC=KHGTPUUROVH=+-B71(0;D[D6:$04KD2%M:
MN5C13:6\<1&AWVAC>$#?M5]KJU4BN:RT406;IM)J0$NV-CR:C<+G(=T),W[
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M;UJTQ5TQU'[I$E+H^S_&HU#5"NC,MW35KGT!LY.9D/Z(L;TO7-Z>GL
M_/PU&.:I;6DV?OI^U7AM* %/3G?;^=/^=\0$%S>=)<%KP=MT$)/S)#I#J<>]
M%,S&^'0HP)&O>71I,QWTW$7I/:]\ I_.>K\^P_%ILCV=/8O4BI&%C522=)E1
MNN[SH .B%27Q"G-52A:O$ PGKV-*(,H!99@J$/!8C".CU^@K2)C=T+82?=O:^NNF?%_GCW.$/-84P',EQ"=3Q\8..58 $M-7V@0W!7CY,^V"2@UAU[-1VH/WW.SLAHZ)%2(GO
M2R'-)"BLK6[#T&0%ELST5862ONR4+IDE4^]#4VED
MN4\J19A$T4U8,BZ#Z=C[5GHZ5K457.)*@ZG+DNF7.0IUG 1Q<'*L^;ZPSA%.
MQQ7;XP;MSVJER0H[E)R7* U7$C3N)L$LOIT/7+P/^,7Q:,[6X)1LE7ITQM=\
M$D2.$ K,K$-@]#K@ H5P0$3CJ<4,NBU=XOGZA/[@M9.6+3.X4.(WSVTQ"48!
MY+ACM;!K=?R"K9ZAP\N4,/X)QR8VI1VSVEA5MLEDEUPV;_;7;Z35F$.(*/L*FW
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MG?=<4.6N.S.EU)A!-3LN(#=NJ T)-
M%T[WP-_FM/\&T=;S^>3YQDS.GF#.^X@*0)Z'OCQAM4#ZGLZXPT.H>#MZY<>-;,)>J]'UF&
MREA+V_1UY^VFXJP9!O_#FY%*[;/GTH# ':5&_4_# '0SIAK#JLJ/AJVR-&C\
MLJ#)CMH%T/>=HH*VAMN@^Z^8_@-02P,$% @ ]H*L5,L.$_=$" 5Q<
M !D !X;"]W;W)K&ULG5AM;^.X$?XKA OT!5!L
MRTZ<9)L$<+*[USMTK\'Z]EK@9H2PKJ:U>"NS&$B7.
MZ_/,#'6SM>[);Y0*XJ4LC+\=;$*H/HQ&/MNH4OJAK93!DY5UI0RX=>N1KYR2
M.6\JB]%D/)Z-2JG-X.Z&UQ[=W8VM0Z&->G3"UV4IW>Y>%79[.T@'^X6O>KT)
MM#"ZNZGD6BU4^%8].MR-6BFY+I7QVAKAU.IV,$\_W*<3VL!O_*S5UG>N!;FR
MM/:);K[/;P=CLD@5*@LD0N+G63VHHB!)L..W1NB@U4D;N]=[Z9_9>3BSE%X]
MV.*?.@^;V\'50.1J)>LB?+7;OZG&H0N2E]G"\U^QC>_.S@7%G_=7?[D9!>BC7:.LD7T?94].
MR)Z*+]:$C1>?3*[RU_M'L+,U=K(W]G[2*_"+=$,Q31,Q&4\F/?*FK?-3EC<]
M(>^8P[_,ESXX@.77'@7GK8)S5G!^0L&]]-H+N^J$-HFJ=N*7YO! M+J.8C6)A86)JC'2[5A$:1DOG@0$K?SQ;=6\>?Y
MXC[A599,2]H@7S5SW(M@!9%5I&/Z]R\!Q&2;%C()-CBEWJS2GW1X_)&Q 6S;
MB8\J4^52N?;)D!^]74Y%#V@N6M!<](+FFU?D[B-"*C_'L1TRO].&+>JF2P
MQ)3&W.#A43P@50 -Y5"'72?;3OU6:XA_A18DIY1/2JA6#252>G2$JDG?1@8A
M5RN4;-X)"ZPC,,J2Z,,PP/LJQ*V%EDM=Z* ;4;GV66%][=@;&$:$@YTG]T0M
MA/<]P(YZ2?M.F:->T" ]A.6U(U8=WJ.["GBW^5#\ _!&%,W:TNJ2")J\BHUZ
MED7-,=&0>XA0[6G#1J,1.%3I@O4YK8A<9):%$"=6J%?60:0V60%2-W9DM7/D
MOD(H;*DSHYH)J#LIY0?ZB[)(!@R[3B'ZAFC0E5RVJAE
MA1JA
MA%[T;@_[ZH+ ]QA7CE$I=B)E;,E),##@Z)A'\EG+J^YVK&L'LO[WL5'N?][[""2T$FG>.>T0%^![U__,/5)+W\JW]5V#M^'%"9
M20]8H38 [BVU&CAX43#U8@,:$IA!^U?XI$0_H=#HT-^_+4J^RXUEZ;0$<[:CO
M)*WC>"RDE0VXP2, &66#@O.F'&==R9S5+(IV))K& 10>- (D4%(
M6:(>Y/0:*2JP!;RAKLW,H=FG)\#7;8"O>P/\A>U@$B]41O+U^P>87A7'@]O1
MZUN]KP-;H'^AL#=MHSRZ ?&4SU(7M'Z&UG3FD:*DP6JL8NJ_0TOQ_C9<#,7:
M/BO'W17D6(:N9 [_V]CK2(4U>E;@3B7-_TY%.CX<[<:]R5A0#][8@N#T)T9<
MV+TW%_TJCB?C*YJS0[%A_6)18=JB 6B..E*(]&H_BZ]"HY[_".X]W?KHU8@#J2,R@6=Q3)A\+R@
MYP07SP^TY[FHIG%RN$Q)PM1\*@&V6%FL[)W]PM:!IB'6V RN2@+C^WGUHR[8LF.&1QK$T5[QK(X.
MOZ)ZE>SG)77H/:CK1!8Z8#BJ;@2-IHWY3H78E[/X1M#D-'$H>;6"B&-&HZ;
M;B2OG=IB2I&Q.$8GFV&5^%ES[<1&1 -QS<)>1FR56QX!XT"X/W]JS+M\B(6I
M<-KQ\$D'@Z,A'6)H:C*Z'[^7G/MX,#D93LPZ0&5/DI/?F6+8)[6):?&R5#Q:
M+W$^0,,NLKIH>GQGB*)30^/^!D=X>3!/O:#O0S/;301M=)#!=.ZEPKJR16&W
M?,CIS!F''8?:UP6;Y, =.8 ?77LXEEZ1IFER=9WB=Y)3<0T&<_&8C*=)K/II4@OKY+IQ75O29H<2M*D
MMR3]J+:O/JWA (;K3/U?0WZ_KE/U.(LCUCQ'D.#_26L(PS_4A@OR+.&_(ITF
M)TX&S1A*A8\H_ 4GKSJRI#.DQJ.A7_4
M^=:)-KSF+[I\AC,A?O9L5]NOQO/XK?3P>OSD#,2MB3&%6F'K>'AY,<#@RU]Q
MXTVP%7\Y!8N"+?ERHR1(22_@^JLX!*W&DS7-$S_WJ!0QV60!,\']WQ?6W<0
MK18MVV..]K'=:MI%(TK)&Y2&*PD:JV6P3JXW$^?O';YQ/)H7:W!*=DH=W.9+
MN0QB1P@%%M8A,)J>\ :%<$!$X]> &8Q7NL"7ZV?T3UX[:=DQ@S=*?.>EK9?!
M/( 2*]8)>Z^.GW'0,W5XA1+&CW ., BLY8U0S!Q*#ALI_9:?<7>98?F66KA59'T,Z;T-S"2_711(Y+]RBYU63E%&=77Y5%R. #;)CA!E0%
M6XT&I65]TF0)>?]>SI;SO>05+YBTL"X*U4G+Y1ZV2O""HX%W#VPGT+Q?1):X
MN1NB8N"QZ7FD;_#(X$Y)6QNXE266_\9'I&D4ECX+VZ1G >^8OH L"2&-T_0,
M7C8F*O-XV9E$&>CUG8&;C' 3#S=Y RZG[BH[@2ZK:\IBR47GZA-R+#K-K';P@"<+&Z&*P\_7WN$L
M+_<'7)N6%;@,6E<(^@D#E\NB'I/IAL31:8@)%6AQ@"/3FFK"0)(DX?PJH3D-
MKV89Y-ZL6L?:66?A=#:!61IFV0P>Y1,:2_KH(JMYX98]'B/ TL T3.8I9&$\
MBR'-LG"674)R.0^SZ16\]@;1BSYH4.]]MQOP==JWQ'@Z?BCKOH_^NO>_$4G>
M[^@-0
M2P,$% @ ]H*L5)1O]? ^ P "0< !D !X;"]W;W)K&ULC55M;]LX#/XKA*\XM( :O[^DEP1HV@V[#SL42[O[<+@/BLTD
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M;(U5]<&9,JA%T__YRX&'$X,V[Y;*+5'K2S)C2WZ$KM
MO"DYT;BF+*RF74%^=O:7L@@)7,,=-QO6?>'#MU8\4AT/SRT/,>1\S>B=F#)]58S<&/C055C_Z^Y3_4$1T
M+&(>G06D!$<0APRB((K.X,4#*7&'%Y\AQ4!?WQFX9(!+.KCD';@%W:2J)?;4
MJB?8D?H3T_]T\> 17RS,I2JW_[[%[-E([@;?F!TO<>K1%36HG]%S[)2;@1ZX
MQQ+K)>JC)NQ3$0V=[F8KFC4MC16V=;?&P 6$+(XR%N8%K>. Q4'!@CQU/<17
M.HKN;,"J;2H#*0N2C&5!#CD+@I0E10QWJJY1EX)+V/&="\N2\9BE20J__U9$
M8?0'/"I+NQL3@.7*"!HM1F I@FGU*RR5
MZU/, N*VR,:#^Z7#=+ZT%23D& Q=B2*61P2=A3^&2R@&=>>J-\D*=S+B-YOE
MGXPG*F;=#6%#;+2-[2?5H!WF_&T_WKZ;]X\$G>6UXTSBBER#44[]T/W@[06K
M=MVP6RI+H[-;;NBM0NT,:'^EZ&X?!!=@>/UF_P-02P,$% @ ]H*L5.;5
MKCXF P ^@8 !D !X;"]W;W)K&UL?57;;MLX
M$/V5@791)( VDB79<5S;0)QNT *;(DW2]*'H RV-+"(2J9)4G/S]#BE95HK8
M+S8O,^>Q LYS7;X#V:[_6MHEW0HV2\0J&Y%* P7WB7H]DJL?;.X)'C5@_68"-92_ED
M-U^RA1=:05AB:BP"H[]GO,*RM$ DXW>'Z?64UG&XWJ%?N]@IEC73>"7+'SPS
MQ<*;>I!ASIK2W,GM9^SB&5N\5);:_<*VM9U,/$@;;635.9."BHOVG[UT>1@X
M3,,##E'G$#G=+9%3^8D9MIPKN05EK0G-+ERHSIO$<6&+K3>6"(V@($:4>S:FFB
M S0QW$AA"@W_B@RSM_X!2>YU1SO=J^@HX U39Q"/?(C"*#J"%_=YB!U>?"0/
M&MKXCL E/5SBX)(#RJ6K7\MI+ ##VH6BIC)62,
M6N!;0PG(H%8\I3SPW7.A5E-/5CT]?^ 9^?*4FH*U(9W\A\]8PN@4[OE&\)SN
M"%R: A7(M97@PN*B;O;6T5OK1ARTC$^!RIP6?9UG<,5T ?B[X123;1++.+_QI
M,AUXOO=8@L$\HB@W;NIJ2&4C3#N:^M-^L%^V\VQOWGX5*'T;+C24F)-K>'8^
M]D"UD[;=&%F[Z;:6AF:E6Q;T<4)E#>@^E]38W<82])^[Y?]02P,$% @
M]H*L5/R.68N9 @ @04 !D !X;"]W;W)K&UL
M?53+;MLP$/R5A9!#"ZC1TY84V ;B)$4+-&V0I.VAZ(&6UA812G1)*G;^ODM*
M5ET@\47:)7=F'^1PMI/J2=>(!O:-:/7.LM9F[M3BUFLC."MWBG0'=-P]3+$H7*?*"D:7B#;::RQ84KN?>972Q3&V\"_C!<:>/;+"=
MK*1\LL[G:NZ%MB 46!K+P.CWC%%!VVLAF %,%#6_[/]L/
M&L/Y<$HVN6$,XNO
MTB!,X0-";J5'!5:<4M@:^<+;B@AM.N^\>V4J@?C\+
M#%5AN8)RR+CL,\9O9$S@5K:FUG#35EC]CP^H^K&%^-#",CY)>,O4.221#W$8
MQR?XDG$DB>-+3HQ$0]_?";ITI$L=7?H&W=LS_.5RP"/N#2R%+)]^OS;-D^Q6
MLQ=ZRTJ<>R1*C>H9/3N1LAY' M=88K.B(H:5:#SL+7M14@AWU@=;H6"&]O!P
M$&UL
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M%_V?[88\' &FX0E / !BYWXL(?R8!3M
MA[",SQ+>,N5#
M$HT@#N/X#%]R2$GB^)(S*='0QW>&+CW0I8XN/4'W0'U4=C6"7+^<9*LW>LZL
M5.!:0\,WYP-\QIV!94W(?U_*]EEUV].7NF4%SCUJ6HWJ";W%I\YH0V?+Q0;N
MF=@XWW"'JN :H56\H"]2ZU9,(5SO6JZ8ZZ&2V=0,%:%=16SW?G.M.RRI46LR
M*L%(,!7"#1,=-3N=332%XA@HUVM4UH,X&65)#A?C//IP]F2?X<%-BM* "FGKU+^*)_VR)/R
MZ2C.*-QHXH^CP=57JASY=U(E(Y648HS\;.I"3/T\_B4R&^M-)]#.QO\CPW%X
M0CR*1BGQ7V1C/QN3L2JJW]#@X@D)H?: YU)-1WEN#Y+*Y3CUKQ1ZCRNU+[3H
M1$0)%6E*IY:E?CC]"9%1M-%HFD?PTF41'%W-#:J->X TB73"]+?T8?7PQKWM
MK_9G\_Z!I#1NN-!0XYJ@H3\9>Z#Z1Z>?&-FZBWXE#3T;;EC1.XW*&M#^6M)-
M,TRLP.'E7_P'4$L#!!0 ( /:"K%0ZKCG:0P0 +(* 9 >&PO=V]R
M:W-H965TB1M)_OU.U*VYJZNDJ)?))*ZU^>>.W&RE>I1+Q$-/-6B
MT5-O:Q#.)BM6X2V:CZMK1;NPLU+R
M&AO-90,*%U/O(CZ?CZR\$[CGN-4':["9/$CY:#>_EU,OL@&AP,)8"XQ>&[Q$
M(:PA"N/OG4VOF;V7!B&',[@ULG@\LPF6<"EK*KIF#K>3
M._8@4)].0D/^K%98[&S/6]O)5VRG\$XV9JGAJBFQ_%P_I#B[8)-]L/.DU^ [
MI@)(8Q^2*$EZ[*5=\JFSE_8DKZ'-K\?)GY0 "LUAV:-I'##5[/NJ\F%EPZ :V '!S?,KJ]#K]7@5
MWJ_K!U0@%SN?&CZYJ6$9L2$T*R0P4!6EU9;""Q#^C4LD%N!DX$?CR,X
MA5$6I"E\6!MMB" V2'+S/\;%\=#/AM9-/!P$5/8\R,?6:>K'PY2:Q2'A2O&E
M)TX+Z]H9XJD2KQS%&4
M\/,/>1(GO_2A.NI0'7U?8],T(\J[P%IH/S;'.?]P;Q4I];CT>ZO+(-!:5%
M<,&X>KDC,S^+6K8'HWS/[Y/X%$[29$3]EF1!%KW0;YD?YVZ 4V\.CQ8@/+A'
MU*@J=UO2-%_HW]1>*;K3[D)VT=Y#_A-O;W/DNZ)I P(7I!H%(QJ7JKTAM1LC
M5^Y6\B -W7'<&PO=V]R:W-H965T%S9L7QBW0)*X
MHGOW$_N%E.7[Q-^,FST8 ZNDIV4!Q=\R>9!
MZ PAQ]0X!FJ'$RZ12_V*9*>;!;0 9
MYK3F9B.;S]C5,W-\J>3:?Z%I(
MO.]6R+M<44.36,D&E,NV;&[B2_5H:XX)=RA;H^PNLSB3?)4&80(?X9O:4\'^
MT+97(H,5ZE2QRL+]"0QG7\!W/IJ;\0TR,->+H2-J)+EK1Z(+H
M?:7&,+D=011&T;]P8OWW141]$9'GN[K MZUW&H\U"@,/)_?]_8CE#M43_(4-
MGE!IA*V1Z0&V%6?]-CR]H3WMM:=O:SO>0O+,JKR#AV/-S#.XKHZ&DB-82N&,
MN&YN7)/_U[56:>:5W&LZ);,P)J>A.S(X:O=J'JG:,Z&!8VY!X?C&HE5[$]O
MR,J?_DX:>Y?\M+"/%Y5+L/NYM%Z[P%VH_G>0O !02P,$% @ ]H*L5+"-
M8IZ; @ V04 !D !X;"]W;W)K&ULE91=3]LP
M%(;_RE$T:2!U39K2C:$T$BU,XX*I:MAV,7'A)B>-A6,'VVE!VH^?/T)6ML"T
M&\=?Y_7S'L5%HW9V&H\@IKHL:B06Y62B%KHLU0;D/5
M2"2%"ZI9&$?1^[ FE =IXN96,DU$JQGEN)*@VKHF\G&!3.SGP21XFEC3;:7M
M1)@F#=EBAOIKLY)F%/8J!:V1*RHX2"SGP?GD;#&S^]V&;Q3WZJ /ULE&B#L[
MN"KF062!D&&NK0(QGQTND3$K9##N.\V@/](&'O:?U#\Y[\;+ABA<"O:=%KJ:
M!ZT,^TR._@2JD6
M"[AHI?.+DHIB!)\D\689"Y\T:PQAU*A>##LH91#4?&H>I"9
M [&/:9=&2;@;8)_V[--7V0=@!J&71%4CN#8_,FT8.MY",$:D@@:E)[;HO],[
MA.]93@_P)_'XXW38PDEOX>1_+3S]0'#[RO7.>OW9OZ^W$JPPI[R%R_N6ZD>P
MCV+T/&M+P2V(?1-K^S2&$C#[Z_YF?UY@>/!2;=&[)G)+N0*&I0F*QA],M/2%
MQ ^T:-SCW0AM2H'K5J;VHK0;S'HI#&LWL/6@K^;I+U!+ P04 " #V@JQ4
MA+W8FM@2E>20_/NN9.,2($PN
MN6!]['MZ^VSM,MD*^:A* $V>ZXJKJ5-JO;EV79654%-U)3; <6U:4
MVBRXR61#"TA!_]PL)<[!OQBL%5[8V(R60GQ
M:";?\ZGC&4%00:8- \7'$RR@J@P1ROC;<3K]D0:X/]ZQ?[6Y8RXKJF AJ@>6
MZW+JC!R2PYHVE;X7VV_0Y1,9ODQ4ROZ2;1?K.21KE!9U!T8%->/MDSYW/NP!
MD.8:HF[
M#'$Z^2$TD)!R@K.UBRC7)-9EHF&:\8+
MLA05RQ@HI+EKM-*(,LLWK&K,2R(I9(UDVD1\N@%-6:4N,%:5%,^:N!KS,&K<
MK-,\;S4';V@.R:W@NE3D"\\A?XUW,?_>A&!GPCPX2WA+Y14)_<\D\(+@A)[%
M^^'^&3EA_TY"RS=X@V^&KE[F._/4GGF,=Z9=G'*M98TLJ[F]3TD0AG$XG+A/
M^\D]Z,%9T0]42O-9_+Z%>@7RSQD?HIXR^A ?HN,$?7\T
M]@]\.!46C./PM ]Q+SH^*SHUNB[Q-D%.EO0%"QY>%6-- 6;\F=QM[,UZAT_#
M_LCAA_@T/&% ',6# Y^.PV+S79VV:=1K'IW5? ]*2Y9I="G5(GM\CQ_CGGO\
M(7Z,CQ*-_%%PX,9Q4.C%WH$9[EY!KD$6MD\I8@MF6Y;ZU;X5SFP'.%B?8XML
M.]I_FK:_8M$I&%>D@C52>E=#E"3;GM5.M-C8LK\2&IN('9;8YD&: -Q?"RS]
MW<0&PO=V]R
M:W-H965T@&:
M;1#W\K#8!UH:6T1X<4G*=OOU.Z04U=UUU&X?]D4BJ3EGSHPT,YKLM'FT):*#
MO13*3J/2N,JFDW"
MV;V9373E!%=X;\!64C+S]1J%WDVC0?1T\,#7I?,'\6RR86MTBUN6
M@DM4EFL%!E?3Z&KP[ &'\E2ZT>_>5M,H\0+0H&Y\PR,;EN<
MHQ">B&1\:3BCUJ4''JZ?V%^%V"F6);,XU^(S+UPYC2XB*'#%*N$>].X--O&,
M/%^NA0U7V#6V201Y99V6#9@42*[J.]LW>3@ $,]Q0-H TG\"AL\ L@:0A4!K
M92&L&^;8;&+T#HRW)C:_"+D):(J&*_\6%\[04TXX-_M#.X0A]&'.;-D+5[C]
M4O$M$ZB3
MV)$T[R#.&QG7M8ST&1D9W&GE2@NWJL#B1WQ,(;5QI4]Q7:>=A*3Y#+)!#](D
M38_HF7?#;S!OX8,..5F;YBSP#9_E6[J#Y/7@:DNY\RGM4R7V%Y3M'GS0CHEC
MN:NYQX';E^5VEJ;CBR1+LDF\/0SJWX9):_[F&K>]BI^^BK[\%[5Z+INY*I
MOD.YT88: +R5&\8-5;B#=]K:8X'4SD8_US=J]8U^1]\#,L&_80&OJ8_!B9=S
MVH/;?2ZJ@JOU;^L?_6I^QZW^<;=^KKBL)/QYAW*)YJ^.3^V\I3S_[RF!.967
MH9Y)A4KU[/SQ5S@)17>T7+M]9"!#N7;(O6CE7OQ$[OY7,W#94E[^#QGH]C%(
M.U(0'_1CB68=QI2%7%?*U:VY/6TGX548 /%W\WJ,4BQKKBP(7!$T.3NG3]#4
MHZG>.+T)W7VI'E ( %D' 9 >&PO=V]R:W-H965TH6;>':0\._!*L&$QM)VF__6Q#69JD
M41_Z C;<'7<'V-F6BY6L !1ZJEDC1TZE5'OMNK*HH";RDK?0Z#L++FJB]%0L
M7=D*(*4EU:<
MK\SD>SERL#$$# IE%(@^;6 ,C!DA;>.QUW2&1QKB[OA%_=9FUUGF1,*8L]^T
M5-7(21U4PH*LF;KGVV_0YXF,7L&9M$>T[;'80<5:*E[W9.V@IDUW)D]]#SL$
M+WR#X/<$_[V$H"<$-FCGS,::$$7R3/ M$@:MUXH%C,EK
MTME$PRF3YQKT,)N@LT_GF:NT6_-,M^B=W73._#>HL"[0#[V_2/T\6GZ
M!(J![KVFN[JCH2A_*,JW>N$;>D/8P@S@?]ICR3JIV$J9_VB37Z6)'P0X[
M$0YQ01)X012E _"5V6 P&YPT>T.:%?JI_S8T@99+JM_)GSNHYR#^GJ@B'-3#
MCZNBDXIV(GJ!'WM)NE?%(2[ 4YQ$AVO(AK,1B?-WO$&GOM/&-VNF_)=5<2#
M>OQQ5<0'$2,OC5AU=741CM]7"(PWL-N#L+G]ET]&M>TD8B!@O-P9>)+E%T"WDW4;RU
M:^&<*[VRVF&E]SX0!J#O+[A>#_N)65Z'W33_!U!+ P04 " #V@JQ40R@,
MN_P" !+"@ &0 'AL+W=O(0'KB76-KV;8-X!RQQ.%K6R-D0EEQ?FS
MF=S%$\LQ'@!D31+]>80:,&4O:CY?:J-5P&F![_&']M@Q>![,B$F:<_:*Q
M2B;6R$(QK$G!U /??HY*U.1 N
M!P< ;@UP3P5X-< K ZT\*\.:$T6F8\&W2)C=VIH9E+DIT3H:FIG?N%1"?Z4:
MIZ8_N (T0%_1C,CDHGRB;R\%?24,,B41R6)T3\0S*+)B@)80%8(J"E)#NM?/
MYGJ-,GFN=SPNY^CLR_G85MI50VA'M5LWE5ON ;>TZ4ODX0OD.J[; 9\=A\\A
M:N#X,]S6"6JRY#99""N@B]/?XW3=8.1XCM>P5M7A[_V- QD)&K^"4S.R,!FY0/K@
MH+LL8D6LJV)+55*='7->]@[1[WM(5R#^'*G$8>/(L&2A,,A#IS0[4[!
MJ&$>]2Z*T:F5:D86_2<+\2O3#TPFYF[.R4T>E1BS7X+')?JIKV19B/>VL)Y017@G:+BOHM4&V@%Z#O9&P:'$[B0-]]XPRP_W_,=NNF-VV6OB'@$ !*&@ &0 'AL+W=OD27$)H7Q(#'L_,?^P?!D9;+A[EBE(%?B9Q*L>]E5+K3XXCPQ5-
MB+SD:YKJ*PLN$J+TH5@Z=4W:]OA3YRRE$BEM!4,IX"01?C
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M;GY-P](37CF8R/I;*S#0K;?!%M)@@% Q>[>.1L#H.N
M=G3+'B_BPF5./
M'QG;D+@H[C\SFCQ0\:]%(*\,Q#M#H)VM?Y W' ;] /KX>/I^Z=6W>KV?@Z^B
MF)A/8)Y/0Z88;9174'H(SL@KJ.2%7=>#?DU5^Z73?D.G%[J6ZTS)"_ 7W= 8
MP#(W\!\X[&8688/D!V4< _OL>IXY8=Z@9N8U&)8Q#,\H
MP+#BM$9ZZ!HZNE:'7[G2JVE1TI 4_#M*,/>TE.$!H>';3P#=X0$]K16:\.ZH0QT! 6VA%[$F7@
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M05]?<*Z>#_+/">7GH\G_4$L#!!0 ( /:"K%382;F8D0( -T&
M 9 >&PO=V]R:W-H965T)[ :3
MULHSLW;'\XSM)"4MW'$D=DV#^L)ED"I#J0P_@TQK?&36G@\/D3_8G)7N6RP@"6C?TDIZX656*B$"N^HO&?[
MKS#D$^IX!:/"/-%^\'4L5.R$9,T@5@0-:?LW?A[J<"1P@S<$WB#PWBOP!X%O
M$NW)3%HK+'&><;9'7'NK:'I@:F/4*AO2ZEU<2ZZL1.ED_I-)0!'ZA&Z*@N^@
M1)^?U0$1(!!N2_1+UL#1UW%9%
M&BOEC97R3+S@C7B')#O\PAFEICZ',0>*I;+!4("Y9/OHD8FN[]93[J=I$L29
M_72W5_#^".^_#YZS"H2^@IBB"N9)^U#A$8(;>%&4G)!.W;P@
MCIU@GC0828-WD1;*0 I%*>2NU"?N7&V#&>+8<]WT!'GJ%R=1&*?SR.&(')Y%
M-K=D#BN<8GEJ,T^IIFY1F/KA/%0T0D5GH7XSB>D<5#0Y8)[>7M\_H9KZN6GB
MN,EIL>RCYJ,;O[JV6](*1*%22NX!5UEZRNX94ZH\_LVOCN,4FG+9<&*]WYYUG9O9KM)?J
M06\0#3RE(M-C;V/,]K7OZWB#*=-7JN0);3
M=JZHY5'SS-9]813UN;PO748OK-UMU!>&P U$017K#%.H&D>EID0^L)O)I
M,8.+5Y>OP(="KU5U=H9J-VQ'\RG-5:ZC*M>14^VUJ$X%TQKDZI!%D K<0M,=
MN'O:3<)A,!B,_%T#5[?BZI[FDMF.JFZ7(<$M
M4''4,(4YK4!4%JJH/<^,_'$V?/V Z1+5O_ =%OE2XV..%-7=SCX/?2?RUJOX
M>O^'S[KNP,(E"8H^\V+F;GO'F0OHUYRY?D76_V6R]UKG+V/UC["B-JCK"NKZ
M)%1K <\HR:#R,3CIXR?ISJ$.?"GPT'!IN6>TO3<%P72]9OYG[IN*^^;V*$1-U:9Z<
MN;+"X'G[#TZ[=G[*N3K+%<_6,"<[3EXE$N 11Z2N)4CGM+I5;O;5N&2TBHM/@*4OUESD5"E7X4
M"UNN!- H-TIBFSB.;R>4I;W)*']W)R8COE8Q2^%.(+E.$BI^7$',M^,>[NU>
MW+/%4F4O[,EH11?P .K/U9W03W;52\022"7C*1(P'_<^X/=7+LD,\A9_,=C*
MVCW*AC+C_#%[N(W&/2=#!#&$*NN"ZLL&KB&.LYXTCN]EI[W*9V98O]_U_BD?
MO![,C$JXYO$W%JGEN#?LH0CF=!VK>[[]'XMN\F'FEMK<"S-
MHO*@A/[*M)V:?.$*T "]0P^*AX]+'D<@Y"OT\?N:J1^(IA&ZYDFBZ
M0X;$#DN\5P5>TH!W2H6%7/P6$8>0WY"-9.ZF^-_OSM945'R0B@^2]^\U]%_B
ME#G.;3G$MXC7QOB:I:77-^A?=,QS,9#"43]WE"7'9H(Q'@9X9&^. '0K@&XK
MP(KV6RG7$"$-YIJG:3G)MTPMD5H"^DS3MHJ_S.8@,^M]32&8@_FDA
MRJMP>"]%E'= %'%]-SC.4[_"U[\\3QKVE*4L62>G4.=7T/Q6:/!G*Z-.IE TK
M:,,+4S8\H&S@:F") VHM -V2=I['$Z#]IU__G3[+2P9[&8LMOJ$RDMN9O5__N>#M=
M9(DI *2] '3 FWLHLIX5D ;>C/R3D_8 /VT-2Q+O(:9*7_66L*A/Q-G?!9Z3
MI<3H/FG7_2XW\R>,/#2AD$35)AB@!I+P(=Q*YPD*VR
MC8KIG4C#L8 1?_>D'<#_)N,GF(ER_T;PKV>D:W3?;=?]#H-:>JH'U75]KV']
MXYH"X%YZ^>\>+O]]SW)^GF]V[:0N._6<4K%@J40QS+6=8PWTT$1QD%@\*+[*
M#^]F7"F>Y+=+H!&(K('^/N=<[1ZR\\#J.'?R'U!+ P04 " #V@JQ4FM'Q
MA)$$ #:$0 &0 'AL+W=O"E=420*W=L]J5U4^J+3Z3X8,H#5)&9M ^5T/_[&3DA""6FD
MWJV6#R1Q/"_/,V./)]V-D"]J :#):QA$ZJJVT'KYR7'4= $A4W6QA C?S(0,
MF<9'.7?44@+SK5 8.)[KMIV0\:C6Z]JQD>QUQ4H'/(*1)&H5ADQNKR$0FZL:
MK>T&[OE\H 0!3+51P?"RA@$$@=&$?GQ/E-92FT8P?[_3_MF"
M1S 3IF @@F?NZ\55K5,C/LS8*M#W8O,%$D MHV\J F7_R2:9Z];(=*6T"!-A
M]"#D47QEKPD1.0':/"+@)0+>&P&O=42@D0@TJEIH)@)-RTP,Q?(P9)KUNE)L
MB#2S49NYL61::83/(Q/WL9;XEJ.<[MT)#:1#SLE8B^G+N:'0)P,18EXI9B-S
M,@3->*#( [SJ%0M.+C>$A.?CGM.AI=,(J<:6+N.C;G'3'W.XOJQ*5GQ',]
MKT!\4"Y^RV2=-(Z+#ZN+TWUQ!WE+R?-2\CRKKWE$WWC!))Q?'W+6EY)%<\#U
MHBD$
M/BD%?O,*5XFE5#F3J9P;%.&DP%@:B=J$(O20^VZJ2N%VFH"]+5=\C(,FG
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MR/A#0OR@Q=*VUA.AL5&WMPM@/D@S =_/!+;7R8/IUM//.;U_ 5!+ P04
M" #V@JQ4 (L*BH\" 4!P &0 'AL+W=O:&EL"1%)E:27_GV'
ME,(J=FRT0"X2EWF/;Q[)X6@KY+,J #39L8JKL5=H75_[OLH*8%1=BAHXSBR%
M9%1C5ZY\54N@N06QRH^"8. S6G(O'=FQ!YF.Q%I7)8<'2=2:,2I_3Z 2V[$7
M>B\#C^6JT&; 3TR7;-O8P"/96FG!6C J8"5O
M_G37^M !(,_;@*@%1/N WA% W )BFVBCS*8UHYJF(RFV1)IH9#,-ZXU%8S8E
M-[LXUQ)G2\3I]*O00!)R0>9:9,\7QI&<3 7#4Z*H-?K$U.W.M(&0[Y:[R/6;G4HI?4)M%)
MPGLJ+TD6KW>$K^MBUG41&A??RU)I24U!^A]SAFZUX;N;,SP\.>%5%%_MN7,8%O:2PY/C=PH, [FR=5>A
MF#77S85THZZTW]B*MC<^P9+?5.B_-,U[@==M57)%*E@B97 YQ"V330UN.EK4
MMHPMA,:B:)L%/EL@30#.+P66LK9C%G /8?H'4$L#!!0 ( /:"K%2H?&PO=V]R:W-H965T-(V"9IX>_VZ^T\E>2(S
M%0;OE/PS2^URW!ET(,6Y6$O[16U_P9I0[/:;*6G*7]C6]X8=F*V-57D=3 CR
MK*C^Q7,MQ$Y U#\2P.L 7N*N$I4H[X45DY%66]#N;MK-7914RV@"EQ7NJ3Q:
M3:L9Q=G)[\HB#. :'JV:/5T[@BGNA&E;O42_+$JAS=.QLR^P,4]6I%)
MANQ"Q
M*^ A9U\?[^'BP^4'", LA493_7K21(U849FF=R3-K9"BF"$("[^)8DU5#%5.
M#A=946>[A'_@4,:*1Y4@+A.X-V8SZ?->W!L%FP.X>@VNWG_!E2HIA3:P0ETA
M0[!K/(-=F#R).X.XL,XXP9G[,7YLQ:%I?HZ5:QX3ZS>( K#PR"2!D1R
M"H@KV)9O+*;78H.:3B# 9]2SS""L=$9JOE&Z*GNR YKQPXC[#>*^%_&=>[A2
M8AK0*3S'[!P)^WL27O?8\(B$@P;0X%Q [R;G8*\2^W$WB@X3$AEX"U5EF
M@&S*6%&D6;&X@F*=3PG7J:''HM),AL3H3^0J$/6XL_\P!>T*G 0L@KD^$A
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M/7 )FI9^\B]02P,$% @ ]H*L5/D*[RAK @ U 4 !D !X;"]W;W)K
M&ULC53;;MI $/V5D:5*B12P,9=$$2!!+FH?:%&B
MIJJJ/BSV@%?LQ=U= OQ]9]>.2Z1@]<7>RYRSY^SLS'BOS=86B X.4B@[B0KG
MRMLXMEF!DMFN+E'1SEH;R1Q-S2:VI4&6!Y 4<9HDHU@RKJ+I.*PMS72L=TYP
MA4L#=B&);PKG%^+IN&0;?$;WO5P:FL4-2\XE*LNU H/K
M233KW""?L?8S]'R9%C9\85_'
M)A%D.^NTK,&D0')5_=FAOH<30#H\ TAK0!IT5P<%E??,L>G8Z#T8'TUL?A"L
M!C2)X\HGY=D9VN6$<].OVB'<0 >>GF6A7OKP"/C!EZ8V"',
M+&6O].L6+N[1,2[LI4<7S&!G'M!+=J2L.9@9P]0&_?@*O@40_%J@7*'Y/8X=
MB?<2XJP6.J^$IF>$]F&AE2LL/*@<\_?XF$PWSM,WY_.TE7#!3!?ZO2M(DS1M
MX>LW-]D/?(,S? ^'DEX:^7=H)%S\1&8N/[+9SC*$(P$MI416=GLIY.QH6P0.
M&HNH%5USNY)D=M4$$KL@V6@>&.?S(=CM1KWN=?&H1
M-&H$C?XO":]:T/,5W!T_$M-.TNL/SLF)3RI-HMF$?F(ATSOEJJ)K5IN6-:LJ
M]5]XU>_H_6TXE9' -4&3[C7=D*EZ2#5QN@QUN]*.ND 8%M1VT?@ VE]KJMUZ
MX@]H&OGT+U!+ P04 " #V@JQ4(J#7?+H# %"P &0 'AL+W=OQ/601
M))OV4/1 2V.+""6J)&7'P/[X'9*RXB:*D1X*]&+S,?/--P\-9[:5ZD$7B 8>
M2U'IBZ PICX/0YT56#(]E#56=+.2JF2&MFH=ZEHARYU2*<(XBL9AR7@5S&?N
M[$;-9[(Q@E=XHT W9H;FO;Q3MP@XE
MYR56FLL*%*XN@LO1^6(4604G\9GC5A^LP;JRE/+!;C[E%T%D&:' S%@(1G\;
M7* 0%HEX?&]!@\ZF53Q<[]'_
MF7/K(S-L/E-R"\I*$YI=N-@X;?*&5S:-=T;1+2<],_]'&H0I#.#.R.QA8".2
MPT*65"::N4 /X/;N_H?K&[:C1!JXW#*5:WC_$0WC0G^PHJB-XIDA*:S<--#YK0C<_I&,E]<66,^8!M4])G"6C'*
M9,ZH"E:,*]@PT: CFTLAF-)0H_)T+>^G2/5Q]RRF!]R3T^%DVD\^[*%ZMP="Q*10BE+Y+HNV20#TN*[HF!UM4"!J-$71G7U H=DO%
M<_L,
M9$=(-V38JYU S&"3#22;H\TECQ0'.,
M3R?A'X!:^C8$UI9-_ E-%#3%:'J5]O'PAMYI8'6MY",O;7T8]DATV9(+;G;
MM)899S:0UE]O8 _[>],;]G6F\& ,*%&MW72D*6GDB.^WW6DW@5VZN>/9^96=
MS/K.X_-%G_SEV?GBK!0[_Q]02P,$% @ ]H*L5%DD;DBO
M @ *@< !D !X;"]W;W)K&ULI57;;MLP#/T5
MP=BP%NABQTG3M7 "Y-)=@'4+VG5[5FPZ%JJ+)\E)^O>C9-=+FC0;MA=;%_+P
M'%*BDK72#Z8 L&0CN#3#H+"VO I#DQ8@J.FH$B3NY$H+:G&JEZ$I-=#,.PD>
MQE$T" 5E,A@E?FVN1XFJ+&<2YIJ82@BJ'R? U7H8=(.GA5NV+*Q;"$=)29=P
M!_:^G&N30?.WAM\9[ V6V/BE"R4>G"33]DPB!PA
MX)!:AT#QMX(I<.Z D,;/!C-H0SK'[?$3^GNO';4LJ(&IXC]89HMA\"X@&>2T
MXO96K3]"H^?Z,:)ET5[ZS&789^=O1%62"7
MY"V9*B&8Q?I80ZC,<"XMDTN0*0-#3F9@*>.&?(.-K2@_18_[NQDY>76:A!9Y
M.+0P;6).ZICQ"S%[Y ;!"T.N90;9KG^(_%L1\9.(27P4\(;J#NEUST@H=-K<]KS>/T7\+Z6H*E+'OD,>,+.R)P^^L0>2E4--?!0[LJM1I=1
M%"7A:IO_OE&ONVVU0[/?TNP?I3F#'%?J2FNVJ/RUFG,JS\@-W3!1"3*6$HN]
M8V'('#2Y%B57C^"T@4Y1VR%IQ\-?1ITH>GTDW>>MCO-_U='0U"C(IH6KR+91
M2YZHO%5DWI /6AGCBG9(U'$N_3]H&K2:!O^M:<9,JL'M8/O=M1P+51VNR6#O
M),47^^=MWZH[V#]OX5;;$:"7OAL;DKK8]>5M5]N&/_9][MGZ!!^"NF__AJE?
M$;R:2X9GCD..D%'G M.OZ\Y<3ZPJ?7-;*(NMT@\+?,Q .P/&PO=V]R:W-H965T
M50]$!;
M8XL(*2HD93M /[XDI; .8KMH4$0'B&(TZZ$?)>%8@:MIR5:A046E>7
M8:@6!7*BSD2%I=E9"LF)-E.Y"E4ED>3.B;,PB:)^R DM@W'JUJ9RG(I:,UKB
M5(*J.2?R\1J9V(R".'A:F-%5H>U".$XKLL(,]==J*LTL]"@YY5@J*DJ0N!P%
M5_'E=1Q9!V?QC>)&[8S!2ID+<6\GG_)1$%E&R'"A+00QGS5.D#&+9'@\M*"!
MCVD==\=/Z!^<>"-F3A1.!/M.&36,[
MZ :PJ)46O'4V##@MFR_9MHG8<4BB PY)ZY XWDT@Q_*&:#).I=B M-8&S0Z<
M5.=MR-'2GDJFI=FEQD^//PN-$$?P'K)ZKO"AQE+#[=J\%9SL[!?R
MC,.YYW#^+QPL? T+OJV/
M?P-02P,$% @ ]H*L5! K\AL= P +A( T !X;"]S='EL97,N>&UL
MW5A1:]LP$/XK1AVCA5''<>O&:Q+8 H7!-@KMP]Z*$LN)0)8\6>Z2_OKI+,=)
M4UW(^K"E!NY]\.#GI/9Q=[]I/&^",A%[2RP-(SWL]
MG!A C#PYC'P?-T9]=1#U'N:&.&PS/Q[F2FX*$!-GL)%IP8)'*D9D0@6?:@Y>
M.2VX6#ES'PPS)90.C*V\E1*!I7IR<.1FT!0M3\&ETDUL%\']G;;+=X#U# 1R
M(3J!?>(,XV%)C6%:WMA)L[@QOH""=GR_*JW"N::KJ'])-@[-S0:9*ITQW86)
MR-HT'@J6@QS-YPNX&U6& !JC"CO(.)TK21L-:X]V8&EG3(@[>&)^Y,^XE_E6
M37M04=D-K:!VZ&C(.2/RKSN;;;DH7=:I;S93-?YIT
MC#W"V6E9BM4GP>>R8&[S!P<<#^G:+U@HS9]L-&B5F34P38)'I@V?;5M^:5K>
MLZ59M],RQS7WWZ#FOYOG.9-,4[$MVO;^,6?YU8KCJW\EN?FOLBO8J[$]!H]=
MY.5;$)D94R^.(0MO:%3^S+\C-^NSUA.:V'N.W!$-N-O+.-UD7:K;B$1[:K-^"ML
M+TJZ5RP;B\N,+5DV::=Z/FV&@1W8J.T%#KO(37/Y$,DP3(ZF7@53+"\
M)0E\_6R8-O# XD"D/\LU7FV\0_;W 5;3?1V"[13O1&RG>*X!\><-/-+47VTL
M#GA@58!Q)4PR!7O3W:)(@V4G@XZ\/]I3$<9KZ
M$<#\"N(80^!IQ!%, 6C D#ANSL&=\RAB\6]02P,$% @ ]H*L
M5)>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5
MN %(MB6/:(7->=I3W;
M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%
MR=.B':5_' _>%%Z<>54H_D1R.DF6=;:W=GHY&IMJRAYKW:,0E'UDHWU$)1
M;T9FIQFMS98QVXA1,1[/1@WE,OOX8=_7O1Z%!6599;F24.DJ'CA[,;^/NR)Y
MYH:ON.#VYSSSOP7+2,,E;_@KJ^?9."-FJUX^*\U?E;14+"NMA)AG>7?@@6G+
MJ[^JEP[R&UT97V/IZBL%D'DV&T.':ZZ-]2U\_Q08GQDT[DJM5==<6*8OJ66?
MM&IW7&Y<-W 7H^ V?!SVWUT0S_3_A%&MU[QBEZIJ&R9M%T?-A .49LMW)B.2
M-FR>[9N0G<.F;NKMK"[A!#/49AP/ZIO;@AX-<0%D)
M7L/5:W)!!945(SZXAKQ=M %D@4 6 T)^+P+($H$L$T(N'80[P1"U)G<[I@/(
M"0(Y&0QR:5450$X1R.E@D MJM@'D#(&<'1;R"V1'DI,CLTEI$E.
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M=1O =2O$ NKNY*VB]?YETOY%V,=?4$L#!!0 ( /:"K%0\8?4:C0$ $\8
M : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V4V.@D 0AN&K$ Y@
M6U7X-U%7LW$[\0)$6S&"$+HGH[",R_?%W&0WL*
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MO/\[J8[7:_WC]K?E?1.?%\4-9P?_#Y:_4$L#!!0 ( /:"K%28Q"$EH@$
M *88 3 6T-O;G1E;G1?5'EP97-=+GAM;,V9S6Z#,!"$7P5QC8)C.TU_
ME.32]MKFT!=P80DH@"W;29.WKR$_4JL4-4JES@4+O#LS>*7O -.WG2$7;>NJ
M<;.X\-X\,.;2@FKE$FVH"3NYMK7RX=8NF5'I2BV)B=%HPE+=>&K\T+<:\7SZ
M1+E:5SYZWH;'KM3-++94N3AZW!>V7K-8&5.5J?)AGVV:[)O+\."0A,ZNQA6E
M<8-0$+.S#NW.SP:'OM<-65MF%"V4]2^J#E5L6S'G=Q6YI%_B3$:=YV5*F4[7
M=6A)G+&D,E<0^;I*]J*#?F3ICV5WZU?R?39Q@J%U8;%R9FZ7*[XTC:[J$)
M0F1]V?^*)\<@??7[43OMC+)?>H?C_=!VU^)^2=02P$"
M% ,4 " #V@JQ4!T%-8H$ "Q $ @ $ 9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0 ( /:"K%0KZ=I.[0 "L" 1
M " :\ !D;V-0&UL4$L! A0#% @ ]H*L5-;"4O9*!0 HA4 !@
M ("!# @ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%
M @ ]H*L5$60K^;S P O P !@ ("!Z14 'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#% @ ]H*L5.]]&MLG P
MG@8 !@ ("!:B4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ]H*L5$HLE45F P I@< !D
M ("!H#0 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#
M% @ ]H*L5#DJ6F4Q!0 R@P !D ("!M$ 'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#% @ ]H*L5#P<
M8*;H @ -P8 !D ("!55$ 'AL+W=O&PO=V]R:W-H965T]< !X;"]W;W)K&UL4$L! A0#% @ ]H*L5)1O]? ^ P "0< !D
M ("!S%\ 'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#% @ ]H*L5*QWEHDS P !0@ !D ("!
M;FD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%
M @ ]H*L5+"-8IZ; @ V04 !D ("!FG, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ]H*L5- 2BQZ4
M @ 60< !D ("!E7P 'AL+W=O&PO=V]R:W-H965T 0 $H: 9 " @9." !X;"]W;W)K&UL4$L! A0#% @ ]H*L5-A)N9B1 @ W08 !D
M ("!0H< 'AL+W=O&PO=V]R
M:W-H965T&UL
M4$L! A0#% @ ]H*L5)K1\821! VA$ !D ("!+Y(
M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
M]H*L5/D*[RAK @ U 4 !D ("!XIT 'AL+W=O&UL4$L! A0#% @ ]H*L5#]P!/R8 @
MX@< !D ("!6Z< 'AL+W=O&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #V@JQ4F,0A
M):(! "F& $P @ 'KLP 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08 , P <- "^M0 !
end
XML
54
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
55
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
56
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.22.1
html
101
180
1
true
38
0
false
7
false
false
R1.htm
000 - Document - Document And Entity Information
Sheet
http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information
Document And Entity Information
Cover
1
false
false
R2.htm
001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-
Consolidated Balance Sheets (Current Period Unaudited)
Statements
2
false
false
R3.htm
002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Statements
3
false
false
R4.htm
003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Statements
4
false
false
R5.htm
004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited
Consolidated Statements of Stockholders' Equity (Unaudited)
Statements
5
false
false
R6.htm
005 - Statement - Consolidated Statements of Cash Flows (Unaudited)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited
Consolidated Statements of Cash Flows (Unaudited)
Statements
6
false
false
R7.htm
006 - Disclosure - Note 1 - Organization and Description of Business
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business
Note 1 - Organization and Description of Business
Notes
7
false
false
R8.htm
007 - Disclosure - Note 2 - Liquidity
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity
Note 2 - Liquidity
Notes
8
false
false
R9.htm
008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies
Notes
9
false
false
R10.htm
009 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities
Note 4 - Cash, Cash Equivalents and Marketable Securities
Notes
10
false
false
R11.htm
010 - Disclosure - Note 5 - Fair Value of Financial Instruments
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments
Note 5 - Fair Value of Financial Instruments
Notes
11
false
false
R12.htm
011 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities
Note 6 - Accrued Expenses and Other Current Liabilities
Notes
12
false
false
R13.htm
012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants
Note 7 - Stockholders' Equity and Common Stock Warrants
Notes
13
false
false
R14.htm
013 - Disclosure - Note 8 - Stock-based Compensation
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation
Note 8 - Stock-based Compensation
Notes
14
false
false
R15.htm
014 - Disclosure - Note 9 - Commitments and Contingencies
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-
Note 9 - Commitments and Contingencies
Notes
15
false
false
R16.htm
015 - Disclosure - Note 10 - Subsequent Events
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events
Note 10 - Subsequent Events
Notes
16
false
false
R17.htm
016 - Disclosure - Significant Accounting Policies (Policies)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies
Significant Accounting Policies (Policies)
Policies
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies
17
false
false
R18.htm
017 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies
18
false
false
R19.htm
018 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables
Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities
19
false
false
R20.htm
019 - Disclosure - Note 5 - Fair Value of Financial Instruments (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables
Note 5 - Fair Value of Financial Instruments (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments
20
false
false
R21.htm
020 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables
Note 6 - Accrued Expenses and Other Current Liabilities (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities
21
false
false
R22.htm
021 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables
Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants
22
false
false
R23.htm
022 - Disclosure - Note 8 - Stock-based Compensation (Tables)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables
Note 8 - Stock-based Compensation (Tables)
Tables
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation
23
false
false
R24.htm
023 - Disclosure - Note 1 - Organization and Description of Business (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual
Note 1 - Organization and Description of Business (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business
24
false
false
R25.htm
024 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables
25
false
false
R26.htm
025 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details
Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)
Details
26
false
false
R27.htm
026 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual
Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables
27
false
false
R28.htm
027 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details
Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)
Details
28
false
false
R29.htm
028 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details
Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)
Details
29
false
false
R30.htm
029 - Disclosure - Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details
Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)
Details
30
false
false
R31.htm
030 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details
Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)
Details
31
false
false
R32.htm
031 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual
Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables
32
false
false
R33.htm
032 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details
Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)
Details
33
false
false
R34.htm
033 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual
Note 8 - Stock-based Compensation (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables
34
false
false
R35.htm
034 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details
Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)
Details
35
false
false
R36.htm
035 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details
Note 8 - Stock-based Compensation - Stock Option Activity (Details)
Details
36
false
false
R37.htm
036 - Disclosure - Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details
Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)
Details
37
false
false
R38.htm
037 - Disclosure - Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details
Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)
Details
38
false
false
R39.htm
038 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual
Note 9 - Commitments and Contingencies (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-
39
false
false
R40.htm
039 - Disclosure - Note 10 - Subsequent Events (Details Textual)
Sheet
http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual
Note 10 - Subsequent Events (Details Textual)
Details
http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events
40
false
false
All Reports
Book
All Reports
dffn20220331_10q.htm
dffn-20220331.xsd
dffn-20220331_cal.xml
dffn-20220331_def.xml
dffn-20220331_lab.xml
dffn-20220331_pre.xml
ex_373517.htm
ex_373518.htm
ex_373519.htm
ex_373520.htm
logo01.jpg
http://fasb.org/us-gaap/2022
http://xbrl.sec.gov/dei/2022
true
true
JSON
59
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"dffn20220331_10q.htm": {
"axisCustom": 0,
"axisStandard": 16,
"contextCount": 101,
"dts": {
"calculationLink": {
"local": [
"dffn-20220331_cal.xml"
]
},
"definitionLink": {
"local": [
"dffn-20220331_def.xml"
]
},
"inline": {
"local": [
"dffn20220331_10q.htm"
]
},
"labelLink": {
"local": [
"dffn-20220331_lab.xml"
]
},
"presentationLink": {
"local": [
"dffn-20220331_pre.xml"
]
},
"schema": {
"local": [
"dffn-20220331.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
"https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
"https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
"https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
"https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
]
}
},
"elementCount": 292,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2022": 20,
"http://xbrl.sec.gov/dei/2022": 6,
"total": 26
},
"keyCustom": 9,
"keyStandard": 171,
"memberCustom": 10,
"memberStandard": 26,
"nsprefix": "dffn",
"nsuri": "http://www.diffusionpharma.com/20220331",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "000 - Document - Document And Entity Information",
"role": "http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information",
"shortName": "Document And Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"b",
"p",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "009 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "010 - Disclosure - Note 5 - Fair Value of Financial Instruments",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"shortName": "Note 5 - Fair Value of Financial Instruments",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "011 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"shortName": "Note 6 - Accrued Expenses and Other Current Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "013 - Disclosure - Note 8 - Stock-based Compensation",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"shortName": "Note 8 - Stock-based Compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "014 - Disclosure - Note 9 - Commitments and Contingencies",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-",
"shortName": "Note 9 - Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "015 - Disclosure - Note 10 - Subsequent Events",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"shortName": "Note 10 - Subsequent Events",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "016 - Disclosure - Significant Accounting Policies (Policies)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies",
"shortName": "Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"us-gaap:EarningsPerSharePolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "017 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:EarningsPerSharePolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "018 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"shortName": "Consolidated Balance Sheets (Current Period Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"lang": null,
"name": "us-gaap:MarketableSecuritiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "019 - Disclosure - Note 5 - Fair Value of Financial Instruments (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"shortName": "Note 5 - Fair Value of Financial Instruments (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "020 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"shortName": "Note 6 - Accrued Expenses and Other Current Liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "021 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "022 - Disclosure - Note 8 - Stock-based Compensation (Tables)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables",
"shortName": "Note 8 - Stock-based Compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:NatureOfOperations",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-04-18_2022-04-18_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
"reportCount": 1,
"unitRef": "Pure",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "023 - Disclosure - Note 1 - Organization and Description of Business (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"shortName": "Note 1 - Organization and Description of Business (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R25": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-04-18_2022-04-18_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "dffn:StockIssuedDuringPeriodFractionalSharesReverseStockSplit",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "024 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityPolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-04-18_2022-04-18_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "-3",
"first": true,
"lang": null,
"name": "dffn:StockIssuedDuringPeriodFractionalSharesReverseStockSplit",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"us-gaap:EarningsPerSharePolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "025 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"us-gaap:EarningsPerSharePolicyTextBlock",
"us-gaap:SignificantAccountingPoliciesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "026 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "-3",
"lang": null,
"name": "dffn:MarketableSecuritiesOtherthantemporaryImpairmentLoss",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "027 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "028 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": null,
"groupType": "statement",
"isDefault": "false",
"longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
"subGroupType": "parenthetical",
"uniqueAnchor": null
},
"R30": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "029 - Disclosure - Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"shortName": "Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:OtherCurrentLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AccruedSalariesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "030 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"shortName": "Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:OtherCurrentLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AccruedSalariesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "dffn:ClassOfWarrantOrRightsExpired",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "031 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "dffn:ClassOfWarrantOrRightsExpired",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "032 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ClassOfWarrantOrRightOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "USDPerShare",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "033 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"shortName": "Note 8 - Stock-based Compensation (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"reportCount": 1,
"unique": true,
"unitRef": "USDPerShare",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "034 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"shortName": "Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2020-12-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "035 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
"shortName": "Note 8 - Stock-based Compensation - Stock Option Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2020-12-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "036 - Disclosure - Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"shortName": "Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "037 - Disclosure - Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"shortName": "Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "038 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual",
"shortName": "Note 9 - Commitments and Contingencies (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-04-18_2022-04-18_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesCPreferredStockIntoCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ConversionOfStockSharesConverted1",
"reportCount": 1,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "039 - Disclosure - Note 10 - Subsequent Events (Details Textual)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"shortName": "Note 10 - Subsequent Events (Details Textual)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:SubsequentEventsTextBlock",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-04-18_2022-04-18_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_RangeAxis-MinimumMember_SubsequentEventTypeAxis-SubsequentEventMember",
"decimals": "INF",
"lang": null,
"name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
"reportCount": 1,
"unique": true,
"unitRef": "Pure",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "Share",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
"role": "http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"shortName": "Consolidated Statements of Cash Flows (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"td",
"tr",
"tbody",
"table",
"div",
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": "INF",
"lang": null,
"name": "us-gaap:Depreciation",
"reportCount": 1,
"unique": true,
"unitRef": "USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "006 - Disclosure - Note 1 - Organization and Description of Business",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"shortName": "Note 1 - Organization and Description of Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dffn:LiquidityDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "007 - Disclosure - Note 2 - Liquidity",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"shortName": "Note 2 - Liquidity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dffn:LiquidityDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
"role": "http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "dffn20220331_10q.htm",
"contextRef": "d_2022-01-01_2022-03-31",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 38,
"tag": {
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentInformationLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Document Information [Line Items]"
}
}
},
"localname": "DocumentInformationLineItems",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "stringItemType"
},
"dei_DocumentInformationTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
"label": "Document Information [Table]"
}
}
},
"localname": "DocumentInformationTable",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r363"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r364"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
"label": "Entity [Domain]"
}
}
},
"localname": "EntityDomain",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "domainItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r372"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r361"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "employerIdItemType"
},
"dei_LegalEntityAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The set of legal entities associated with a report.",
"label": "Legal Entity [Axis]"
}
}
},
"localname": "LegalEntityAxis",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r360"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r362"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-document-and-entity-information"
],
"xbrltype": "tradingSymbolItemType"
},
"dffn_AccruedClinicalStudiesExpensesCurrent": {
"auth_ref": [],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"order": 0.0,
"parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.",
"label": "dffn_AccruedClinicalStudiesExpensesCurrent",
"terseLabel": "Accrued clinical studies expenses"
}
}
},
"localname": "AccruedClinicalStudiesExpensesCurrent",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"dffn_ClassOfWarrantOrRightsExpired": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of warrants or rights expired.",
"label": "dffn_ClassOfWarrantOrRightsExpired",
"terseLabel": "Class of Warrant or Rights, Expired (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightsExpired",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "sharesItemType"
},
"dffn_CommonStockWarrantsIssuedRelatedToFebruary2021CommonStockOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the common stock warrants issued related to the February 2021 common stock offering.",
"label": "Common Stock Warrants Issued Related to February 2021 Common Stock Offering [Member]"
}
}
},
"localname": "CommonStockWarrantsIssuedRelatedToFebruary2021CommonStockOfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_CommonStockWarrantsIssuedRelatedToMay2020CommonStockOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the common stock warrants issued related to the May 2020 common stock offering.",
"label": "Common Stock Warrants Issued Related to May 2020 Common Stock Offering [Member]"
}
}
},
"localname": "CommonStockWarrantsIssuedRelatedToMay2020CommonStockOfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_ConversionOfSeriesCPreferredStockIntoCommonStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the converison of series C preferred stock into common stock.",
"label": "Conversion of Series C Preferred Stock into Common Stock [Member]"
}
}
},
"localname": "ConversionOfSeriesCPreferredStockIntoCommonStockMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"dffn_EquityIncentivePlan2015Member": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to the 2015 equity incentive plan.",
"label": "Equity Incentive Plan 2015 [Member]"
}
}
},
"localname": "EquityIncentivePlan2015Member",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"dffn_LiquidityDisclosureTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the liquidity of the company.",
"label": "Liquidity Disclosure [Text Block]"
}
}
},
"localname": "LiquidityDisclosureTextBlock",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity"
],
"xbrltype": "textBlockItemType"
},
"dffn_MarketableSecuritiesContractualMaturity": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The contractual maturity of marketable securities.",
"label": "dffn_MarketableSecuritiesContractualMaturity",
"terseLabel": "Marketable Securities Contractual Maturity (Month)"
}
}
},
"localname": "MarketableSecuritiesContractualMaturity",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual"
],
"xbrltype": "durationItemType"
},
"dffn_MarketableSecuritiesOtherthantemporaryImpairmentLoss": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of other-than-temporary impairment loss on marketable securities.",
"label": "dffn_MarketableSecuritiesOtherthantemporaryImpairmentLoss",
"terseLabel": "Marketable Securities, Other-than-temporary Impairment Loss"
}
}
},
"localname": "MarketableSecuritiesOtherthantemporaryImpairmentLoss",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual"
],
"xbrltype": "monetaryItemType"
},
"dffn_NoteToFinancialStatementDetailsTextual": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note To Financial Statement Details Textual"
}
}
},
"localname": "NoteToFinancialStatementDetailsTextual",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_NotesToFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Notes To Financial Statements [Abstract]"
}
}
},
"localname": "NotesToFinancialStatementsAbstract",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.",
"label": "dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
"terseLabel": "Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis"
}
}
},
"localname": "PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "percentItemType"
},
"dffn_PrepaidExpensesDepositsAndOtherAssets": {
"auth_ref": [],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid expenses, deposits and other current assets"
}
}
},
"localname": "PrepaidExpensesDepositsAndOtherAssets",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"dffn_ReverseStockSplitFractionalSharesCashMultiple": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The per share multiple used to determine the price paid for franctional share in a stock reverse split.",
"label": "dffn_ReverseStockSplitFractionalSharesCashMultiple",
"terseLabel": "Reverse Stock Split, Fractional Shares, Cash, Multiple (in dollars per share)"
}
}
},
"localname": "ReverseStockSplitFractionalSharesCashMultiple",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "perShareItemType"
},
"dffn_ReverseStockSplitMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.",
"label": "Reverse Stock Split [Member ]"
}
}
},
"localname": "ReverseStockSplitMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"dffn_StockIssuedDuringPeriodFractionalSharesReverseStockSplit": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of fractional shares were issued in connection with the Reverse Stock Split.",
"label": "dffn_StockIssuedDuringPeriodFractionalSharesReverseStockSplit",
"terseLabel": "Stock Issued During Period, Fractional Shares, Reverse Stock Split (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodFractionalSharesReverseStockSplit",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "sharesItemType"
},
"dffn_TheMay2020InvestorWarrantExerciseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Related to the May 2020 Investor Warrant Exercise.",
"label": "The May 2020 Investor Warrant Exercise [Member]"
}
}
},
"localname": "TheMay2020InvestorWarrantExerciseMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information pertaining to warrants issued in connection with May 2019 public offering.",
"label": "Warrants Issued in Connection with May 2019 Public Offering [Member]"
}
}
},
"localname": "WarrantsIssuedInConnectionWithMay2019PublicOfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.",
"label": "Warrants Issued in Connection with the December 2019 Offering [Member]"
}
}
},
"localname": "WarrantsIssuedInConnectionWithTheDecember2019OfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to the warrants issued in connection to the January 2018 public offering.",
"label": "Warrants Issued in Connection with the January 2018 Offering [Member]"
}
}
},
"localname": "WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.",
"label": "Warrants Issued in Connection with the November 2019 Offering [Member]"
}
}
},
"localname": "WarrantsIssuedInConnectionWithTheNovember2019OfferingMember",
"nsuri": "http://www.diffusionpharma.com/20220331",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)"
}
}
},
"localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies"
}
}
},
"localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)"
}
}
},
"localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)"
}
}
},
"localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 4 - Cash, Cash Equivalents and Marketable Securities"
}
}
},
"localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)"
}
}
},
"localname": "statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 5 - Fair Value of Financial Instruments"
}
}
},
"localname": "statement-statement-note-5-fair-value-of-financial-instruments-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)"
}
}
},
"localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 6 - Accrued Expenses and Other Current Liabilities"
}
}
},
"localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 7 - Stockholders' Equity and Common Stock Warrants"
}
}
},
"localname": "statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)"
}
}
},
"localname": "statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Stock-based Compensation - Fair Value Assumptions (Details)"
}
}
},
"localname": "statement-statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)"
}
}
},
"localname": "statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Stock-based Compensation - Stock Option Activity (Details)"
}
}
},
"localname": "statement-statement-note-8-stockbased-compensation-stock-option-activity-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)"
}
}
},
"localname": "statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-note-8-stockbased-compensation-tables": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Note 8 - Stock-based Compensation"
}
}
},
"localname": "statement-statement-note-8-stockbased-compensation-tables",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"dffn_statement-statement-significant-accounting-policies-policies": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Significant Accounting Policies"
}
}
},
"localname": "statement-statement-significant-accounting-policies-policies",
"nsuri": "http://www.diffusionpharma.com/20220331",
"xbrltype": "stringItemType"
},
"srt_DirectorMember": {
"auth_ref": [
"r109"
],
"lang": {
"en-us": {
"role": {
"label": "Director [Member]"
}
}
},
"localname": "DirectorMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r142",
"r143",
"r144",
"r145",
"r160",
"r170",
"r198",
"r199",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r326",
"r348",
"r349",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r142",
"r143",
"r144",
"r145",
"r160",
"r170",
"r198",
"r199",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r326",
"r348",
"r349",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "domainItemType"
},
"srt_PresidentMember": {
"auth_ref": [
"r109"
],
"lang": {
"en-us": {
"role": {
"label": "President [Member]"
}
}
},
"localname": "PresidentMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r137",
"r142",
"r143",
"r144",
"r145",
"r160",
"r170",
"r189",
"r198",
"r199",
"r229",
"r230",
"r231",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r326",
"r348",
"r349",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r137",
"r142",
"r143",
"r144",
"r145",
"r160",
"r170",
"r189",
"r198",
"r199",
"r229",
"r230",
"r231",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r326",
"r348",
"r349",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "domainItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r109",
"r289"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Domain]"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
"label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]"
}
}
},
"localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r19",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedProfessionalFeesCurrent": {
"auth_ref": [
"r20"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"order": 3.0,
"parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "us-gaap_AccruedProfessionalFeesCurrent",
"terseLabel": "Accrued professional fees"
}
}
},
"localname": "AccruedProfessionalFeesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedSalariesCurrent": {
"auth_ref": [
"r5",
"r20"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"order": 2.0,
"parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "us-gaap_AccruedSalariesCurrent",
"terseLabel": "Accrued payroll and payroll related expenses"
}
}
},
"localname": "AccruedSalariesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r14",
"r27",
"r28",
"r29",
"r341",
"r354",
"r355"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r26",
"r29",
"r35",
"r36",
"r37",
"r63",
"r64",
"r65",
"r251",
"r288",
"r350",
"r351"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r12"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r63",
"r64",
"r65",
"r240",
"r241",
"r242",
"r256"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
"label": "Stock-based compensation expense and vesting of restricted stock units"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r200",
"r243",
"r244"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Stock-based compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r234"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "us-gaap_AllocatedShareBasedCompensationExpense",
"terseLabel": "Share-Based Payment Arrangement, Expense",
"verboseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r84"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Anti-dilutive securities (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r84"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r84"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r8",
"r60",
"r102",
"r104",
"r107",
"r123",
"r149",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r249",
"r252",
"r267",
"r290",
"r292",
"r329",
"r340"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "us-gaap_Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r3",
"r18",
"r60",
"r123",
"r149",
"r150",
"r151",
"r152",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r249",
"r252",
"r267",
"r290",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 0.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "us-gaap_AssetsCurrent",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r259"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "us-gaap_AssetsFairValueDisclosure",
"totalLabel": "Total financial assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r115"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Commercial paper"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r116"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"negatedLabel": "Commercial paper"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
"auth_ref": [
"r113",
"r130"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Amortized cost"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
"auth_ref": [
"r111",
"r114",
"r130",
"r331"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
"order": 0.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
"terseLabel": "Debt Securities, Available-for-Sale, Total",
"verboseLabel": "Fair Value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r203",
"r204",
"r205",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r222",
"r223",
"r225",
"r226",
"r228",
"r229",
"r230",
"r231",
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_BankTimeDepositsMember": {
"auth_ref": [
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
"label": "Bank Time Deposits [Member]"
}
}
},
"localname": "BankTimeDepositsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r2",
"r6",
"r51"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAxis": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of cash and cash equivalent balance.",
"label": "Cash and Cash Equivalents [Axis]"
}
}
},
"localname": "CashAndCashEquivalentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
"verboseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
"auth_ref": [
"r52"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
"label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
}
}
},
"localname": "CashAndCashEquivalentsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
"auth_ref": [
"r119"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
"label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]"
}
}
},
"localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
"auth_ref": [
"r46",
"r51",
"r56"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"periodEndLabel": "Cash and cash equivalents at end of period",
"periodStartLabel": "Cash and cash equivalents at beginning of year"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r46",
"r268"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"totalLabel": "Net (decrease) increase in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Supplemental disclosure of non-cash activities:"
}
}
},
"localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r9",
"r10",
"r11",
"r58",
"r60",
"r77",
"r78",
"r79",
"r81",
"r83",
"r89",
"r90",
"r91",
"r123",
"r149",
"r153",
"r154",
"r155",
"r158",
"r159",
"r167",
"r168",
"r172",
"r176",
"r183",
"r267",
"r365"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class of Stock [Domain]"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightAxis": {
"auth_ref": [
"r187",
"r201"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of warrant or right issued.",
"label": "Class of Warrant or Right [Axis]"
}
}
},
"localname": "ClassOfWarrantOrRightAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_ClassOfWarrantOrRightDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
"label": "Class of Warrant or Right [Domain]"
}
}
},
"localname": "ClassOfWarrantOrRightDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
"auth_ref": [
"r184"
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
"label": "Range of exercise price (in dollars per share)"
}
}
},
"localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ClassOfWarrantOrRightOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of warrants or rights outstanding.",
"label": "Common stock warrants, outstanding (in shares)"
}
}
},
"localname": "ClassOfWarrantOrRightOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommercialPaperMember": {
"auth_ref": [
"r148"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
"label": "Commercial Paper [Member]"
}
}
},
"localname": "CommercialPaperMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
"auth_ref": [
"r190",
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
"label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]"
}
}
},
"localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r22",
"r332",
"r344"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies (Note 9)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r139",
"r140",
"r141",
"r146",
"r356"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r63",
"r64",
"r256"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common stock, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common stock, shares authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r11"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common stock, shares issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r11",
"r183"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common stock, shares outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r11",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common stock, $0.001 par value: 1,000,000,000 shares authorized; 2,038,392 and 2,038,185 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r31",
"r33",
"r34",
"r39",
"r334",
"r346"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "us-gaap_ComprehensiveIncomeNetOfTax",
"totalLabel": "Comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Comprehensive loss:"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskCreditRisk": {
"auth_ref": [
"r95",
"r339"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for credit risk.",
"label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
}
}
},
"localname": "ConcentrationRiskCreditRisk",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
"auth_ref": [
"r53",
"r54",
"r55"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by description of stock conversions.",
"label": "Stock Conversion Description [Axis]"
}
}
},
"localname": "ConversionOfStockByUniqueDescriptionAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConversionOfStockNameDomain": {
"auth_ref": [
"r53",
"r54",
"r55"
],
"lang": {
"en-us": {
"role": {
"documentation": "The unique name of a noncash or part noncash stock conversion.",
"label": "Conversion of Stock, Name [Domain]"
}
}
},
"localname": "ConversionOfStockNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConversionOfStockSharesConverted1": {
"auth_ref": [
"r53",
"r54",
"r55"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "us-gaap_ConversionOfStockSharesConverted1",
"terseLabel": "Conversion of Stock, Shares Converted (in shares)"
}
}
},
"localname": "ConversionOfStockSharesConverted1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ConversionOfStockSharesIssued1": {
"auth_ref": [
"r53",
"r54",
"r55"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
"label": "us-gaap_ConversionOfStockSharesIssued1",
"terseLabel": "Conversion of Stock, Shares Issued (in shares)"
}
}
},
"localname": "ConversionOfStockSharesIssued1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
"auth_ref": [
"r119"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale [Table Text Block]"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
"label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
"terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
}
}
},
"localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
"label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
"terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay"
}
}
},
"localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
"label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
"terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent"
}
}
},
"localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual"
],
"xbrltype": "percentItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r49",
"r135"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationNonproduction": {
"auth_ref": [
"r49",
"r135"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.",
"label": "us-gaap_DepreciationNonproduction",
"terseLabel": "Depreciation"
}
}
},
"localname": "DepreciationNonproduction",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r202",
"r203",
"r235",
"r236",
"r238",
"r245"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement [Text Block]"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureTextBlockAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_DisclosureTextBlockAbstract",
"terseLabel": "Notes to Financial Statements"
}
}
},
"localname": "DisclosureTextBlockAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Per share information:"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r40",
"r68",
"r69",
"r70",
"r71",
"r72",
"r76",
"r77",
"r81",
"r82",
"r83",
"r86",
"r87",
"r257",
"r258",
"r335",
"r347"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Net loss per share of common stock, basic and diluted (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r84",
"r85"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
"auth_ref": [
"r237"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
"label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
"terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r237"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-Based Payment Arrangement, Option [Member]"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Stockholders\u2019 Equity:"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r35",
"r36",
"r37",
"r63",
"r64",
"r65",
"r67",
"r73",
"r75",
"r88",
"r124",
"r183",
"r185",
"r240",
"r241",
"r242",
"r247",
"r248",
"r256",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r288",
"r350",
"r351",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
"auth_ref": [
"r259",
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r161",
"r164",
"r165",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r260",
"r299",
"r300",
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r259",
"r260",
"r261",
"r262",
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r263"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r161",
"r190",
"r191",
"r196",
"r197",
"r260",
"r299"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r161",
"r164",
"r165",
"r190",
"r191",
"r196",
"r197",
"r260",
"r300"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r161",
"r164",
"r165",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r260",
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r161",
"r164",
"r165",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r299",
"r300",
"r301"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r263",
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value, Recurring [Member]"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueOfFinancialInstrumentsPolicy": {
"auth_ref": [
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
}
}
},
"localname": "FairValueOfFinancialInstrumentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FinancialInstrumentAxis": {
"auth_ref": [
"r117",
"r118",
"r120",
"r121",
"r122",
"r125",
"r126",
"r127",
"r128",
"r129",
"r131",
"r132",
"r133",
"r134",
"r163",
"r181",
"r254",
"r296",
"r297",
"r298",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r309",
"r310",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r319",
"r320",
"r321",
"r322",
"r323",
"r324",
"r325",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of financial instrument.",
"label": "Financial Instrument [Axis]"
}
}
},
"localname": "FinancialInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r43"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r41"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General and Administrative Expense [Member]"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r136",
"r138"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r138"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r48"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Accounts payable, accrued expenses and other liabilities"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r48"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"negatedTerseLabel": "Prepaid expenses, deposits and other assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestIncomeExpenseNonoperatingNet": {
"auth_ref": [],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net amount of nonoperating interest income (expense).",
"label": "us-gaap_InterestIncomeExpenseNonoperatingNet",
"negatedLabel": "Interest income"
}
}
},
"localname": "InterestIncomeExpenseNonoperatingNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
"auth_ref": [
"r44"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
"label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium",
"negatedLabel": "Amortization of premium and discount on marketable securities"
}
}
},
"localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r17",
"r60",
"r123",
"r267",
"r292",
"r330",
"r343"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "us-gaap_LiabilitiesAndStockholdersEquity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r4",
"r21",
"r60",
"r123",
"r149",
"r150",
"r151",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r250",
"r252",
"r253",
"r267",
"r290",
"r291",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "us-gaap_LiabilitiesCurrent",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "stringItemType"
},
"us-gaap_MarketableSecuritiesCurrent": {
"auth_ref": [],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 0.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in marketable security, classified as current.",
"label": "Marketable securities"
}
}
},
"localname": "MarketableSecuritiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MarketableSecuritiesPolicy": {
"auth_ref": [
"r338"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for investment classified as marketable security.",
"label": "Marketable Securities, Policy [Policy Text Block]"
}
}
},
"localname": "MarketableSecuritiesPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).",
"label": "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
"terseLabel": "Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss"
}
}
},
"localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
"auth_ref": [
"r42"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
"label": "us-gaap_MarketableSecuritiesUnrealizedGainLoss",
"negatedTerseLabel": "Unrealized loss on marketable securities"
}
}
},
"localname": "MarketableSecuritiesUnrealizedGainLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r190"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_NatureOfOperations": {
"auth_ref": [
"r92",
"r101"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
"label": "Nature of Operations [Text Block]"
}
}
},
"localname": "NatureOfOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r46"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r46"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Cash flows used in investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r46",
"r47",
"r50"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r1",
"r30",
"r32",
"r37",
"r38",
"r50",
"r60",
"r66",
"r68",
"r69",
"r70",
"r71",
"r74",
"r75",
"r80",
"r102",
"r103",
"r105",
"r106",
"r108",
"r123",
"r149",
"r150",
"r151",
"r153",
"r154",
"r155",
"r156",
"r157",
"r158",
"r159",
"r258",
"r267",
"r333",
"r345"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net loss",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonmonetaryTransactionTypeAxis": {
"auth_ref": [
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
"label": "Nonmonetary Transaction Type [Axis]"
}
}
},
"localname": "NonmonetaryTransactionTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_NonmonetaryTransactionTypeDomain": {
"auth_ref": [
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
"label": "Nonmonetary Transaction Type [Domain]"
}
}
},
"localname": "NonmonetaryTransactionTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating expenses:"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r102",
"r103",
"r105",
"r106",
"r108"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "us-gaap_OperatingIncomeLoss",
"negatedTotalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r276",
"r277"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "us-gaap_OperatingLeasePayments",
"terseLabel": "Operating Lease, Payments"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r20"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
},
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Accrued expenses and other current liabilities",
"totalLabel": "Total"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r7"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
"auth_ref": [
"r25",
"r27"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
"label": "Unrealized loss on marketable securities",
"terseLabel": "Unrealized loss on marketable securities"
}
}
},
"localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of other current liabilities.",
"label": "Other Current Liabilities [Table Text Block]"
}
}
},
"localname": "OtherCurrentLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherSundryLiabilitiesCurrent": {
"auth_ref": [
"r20",
"r147"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
"order": 1.0,
"parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
"label": "us-gaap_OtherSundryLiabilitiesCurrent",
"terseLabel": "Other"
}
}
},
"localname": "OtherSundryLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMarketableSecurities": {
"auth_ref": [
"r112"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for purchase of marketable security.",
"label": "us-gaap_PaymentsToAcquireMarketableSecurities",
"negatedLabel": "Purchases of marketable securities"
}
}
},
"localname": "PaymentsToAcquireMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PlanNameAxis": {
"auth_ref": [
"r203",
"r204",
"r205",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r222",
"r223",
"r225",
"r226",
"r228",
"r229",
"r230",
"r231",
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by plan name for share-based payment arrangement.",
"label": "Plan Name [Axis]"
}
}
},
"localname": "PlanNameAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_PlanNameDomain": {
"auth_ref": [
"r203",
"r204",
"r205",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r222",
"r223",
"r225",
"r226",
"r228",
"r229",
"r230",
"r231",
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan name for share-based payment arrangement.",
"label": "Plan Name [Domain]"
}
}
},
"localname": "PlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_PolicyTextBlockAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_PolicyTextBlockAbstract",
"terseLabel": "Accounting Policies"
}
}
},
"localname": "PolicyTextBlockAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_PreferredStockConvertibleConversionPrice": {
"auth_ref": [
"r169"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share conversion price of preferred stock.",
"label": "us-gaap_PreferredStockConvertibleConversionPrice",
"terseLabel": "Preferred Stock, Convertible, Conversion Price (in dollars per share)"
}
}
},
"localname": "PreferredStockConvertibleConversionPrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockConvertibleConversionRatio": {
"auth_ref": [
"r169"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
"label": "us-gaap_PreferredStockConvertibleConversionRatio",
"terseLabel": "Preferred Stock, Convertible, Conversion Ratio"
}
}
},
"localname": "PreferredStockConvertibleConversionRatio",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "pureItemType"
},
"us-gaap_PreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
"label": "Preferred Stock [Member]"
}
}
},
"localname": "PreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r10",
"r167"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred stock, par value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r10"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred stock, authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r10",
"r167"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred stock, issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r10"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred stock, outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r10",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Series C convertible preferred stock, $0.001 par value: 10,000 shares authorized; 10,000 and 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r45"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from the sale of common stock, net of issuance costs"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
"auth_ref": [
"r45"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
"label": "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock",
"terseLabel": "Proceeds from Issuance of Convertible Preferred Stock"
}
}
},
"localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
"auth_ref": [
"r45"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
"label": "Proceeds from the sale of series C preferred stock to related parties"
}
}
},
"localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromWarrantExercises": {
"auth_ref": [
"r45"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
"label": "Proceeds received from the exercise of common stock warrants"
}
}
},
"localname": "ProceedsFromWarrantExercises",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r246",
"r327",
"r359"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and Development Expense [Member]"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents [Domain]"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockMember": {
"auth_ref": [
"r84"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
"label": "Restricted Stock [Member]"
}
}
},
"localname": "RestrictedStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units (RSUs) [Member]"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r13",
"r185",
"r292",
"r342",
"r353",
"r355"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 0.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r63",
"r64",
"r65",
"r67",
"r73",
"r75",
"r124",
"r240",
"r241",
"r242",
"r247",
"r248",
"r256",
"r350",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_SaleOfStockPricePerShare": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
"label": "us-gaap_SaleOfStockPricePerShare",
"terseLabel": "Sale of Stock, Price Per Share (in dollars per share)"
}
}
},
"localname": "SaleOfStockPricePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r84"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of cash and cash equivalents.",
"label": "Schedule of Cash and Cash Equivalents [Table Text Block]"
}
}
},
"localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r233"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
"auth_ref": [
"r206"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
"label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r206",
"r221",
"r224"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
"auth_ref": [
"r227"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
"label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
"auth_ref": [
"r187",
"r201"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
"label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
}
}
},
"localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SeriesCPreferredStockMember": {
"auth_ref": [
"r9",
"r10",
"r183"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series C preferred stock.",
"label": "Series C Preferred Stock [Member]"
}
}
},
"localname": "SeriesCPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r48"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "us-gaap_ShareBasedCompensation",
"verboseLabel": "Stock-based compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r203"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"auth_ref": [
"r215",
"r216"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"periodEndLabel": "Unvested, shares (in shares)",
"periodStartLabel": "Unvested, shares (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r215",
"r216"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"periodEndLabel": "Unvested, Weighted-average grant date fair value (in dollars per share)",
"periodStartLabel": "Unvested, Weighted-average grant date fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"auth_ref": [
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"negatedLabel": "Vested, shars (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r219"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
"label": "Vested, Weighted-average grant date fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
"auth_ref": [
"r229"
],
"lang": {
"en-us": {
"role": {
"documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
"label": "Expected volatility"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
"auth_ref": [
"r231"
],
"lang": {
"en-us": {
"role": {
"documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
"label": "Risk-free interest rate"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "percentItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r239"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r209"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"terseLabel": "Exercisable (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r209"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r213"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"negatedLabel": "Cancelled/forfeited (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r211"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r222"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
"auth_ref": [
"r239"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"terseLabel": "Options outstanding, aggregate intrinsic value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r207",
"r208"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"periodEndLabel": "Options outstanding, number (in shares)",
"periodStartLabel": "Balance at January 1, 2022 (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r207",
"r208"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"periodEndLabel": "Options outstanding, weighted-average exercise price (in dollars per share)",
"periodStartLabel": "Balance at January 1, 2022 (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
"auth_ref": [
"r225"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested and expected to vest, aggregate intrinsic value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
"auth_ref": [
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested and expected to vest (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r203",
"r204",
"r205",
"r207",
"r208",
"r209",
"r210",
"r211",
"r212",
"r213",
"r214",
"r215",
"r216",
"r217",
"r218",
"r219",
"r220",
"r222",
"r223",
"r225",
"r226",
"r228",
"r229",
"r230",
"r231",
"r232"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r213"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Cancelled/forfeited, weighted-average exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r211"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Granted, weighted-average exercise price (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
"auth_ref": [
"r228"
],
"lang": {
"en-us": {
"role": {
"documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Expected term (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
"auth_ref": [
"r239"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"terseLabel": "Exercisable, aggregate intrinsic value"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r239"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"terseLabel": "Exercisable, weighted-average remaining contractual life (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"auth_ref": [
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"terseLabel": "Options outstanding, weighted-average remaining contractual life (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Vested and expected to vest, weighted-average remaining contractual life (Year)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
"auth_ref": [
"r223"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
"label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
"terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "us-gaap_SharesOutstanding",
"periodEndLabel": "Balance (in shares)",
"periodStartLabel": "Balance (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
"label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation",
"terseLabel": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)"
}
}
},
"localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r57",
"r62"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r9",
"r10",
"r11",
"r58",
"r60",
"r77",
"r78",
"r79",
"r81",
"r83",
"r89",
"r90",
"r91",
"r123",
"r149",
"r153",
"r154",
"r155",
"r158",
"r159",
"r167",
"r168",
"r172",
"r176",
"r183",
"r267",
"r365"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r24",
"r35",
"r36",
"r37",
"r63",
"r64",
"r65",
"r67",
"r73",
"r75",
"r88",
"r124",
"r183",
"r185",
"r240",
"r241",
"r242",
"r247",
"r248",
"r256",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r288",
"r350",
"r351",
"r352"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r63",
"r64",
"r65",
"r88",
"r328"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-2-liquidity",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-fair-value-assumptions-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-",
"http://www.diffusionpharma.com/20220331/role/statement-note-9-commitments-and-contingencies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
"auth_ref": [
"r23",
"r162",
"r183",
"r184",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
"label": "Issuance of common stock upon exercise of warrants, net of issuance costs (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r10",
"r11",
"r183",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Sale of common stock (in shares)",
"terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
"auth_ref": [
"r10",
"r11",
"r183",
"r185"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
"label": "Stock-based compensation expense and vesting of restricted stock units (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r10",
"r11",
"r183",
"r185",
"r212"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-details-textual"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
"auth_ref": [
"r24",
"r183",
"r185"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
"label": "Issuance of common stock upon exercise of warrants, net of issuance costs"
}
}
},
"localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueNewIssues": {
"auth_ref": [
"r10",
"r11",
"r183",
"r185"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
"label": "Sale of common stock"
}
}
},
"localname": "StockIssuedDuringPeriodValueNewIssues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r11",
"r15",
"r16",
"r60",
"r110",
"r123",
"r267",
"r292"
],
"calculation": {
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "us-gaap_StockholdersEquity",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-",
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-stockholders-equity-unaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r59",
"r168",
"r171",
"r172",
"r173",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r182",
"r185",
"r188",
"r255"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
"auth_ref": [
"r186"
],
"lang": {
"en-us": {
"role": {
"documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
"label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
"terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio"
}
}
},
"localname": "StockholdersEquityNoteStockSplitConversionRatio1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
],
"xbrltype": "pureItemType"
},
"us-gaap_StockholdersEquityPolicyTextBlock": {
"auth_ref": [
"r166"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
"label": "Stockholders' Equity, Policy [Policy Text Block]"
}
}
},
"localname": "StockholdersEquityPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r275",
"r294"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r275",
"r294"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r275",
"r294"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business",
"http://www.diffusionpharma.com/20220331/role/statement-note-1-organization-and-description-of-business-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events",
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r293",
"r295"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-10-subsequent-events"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_TableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "us-gaap_TableTextBlock",
"terseLabel": "Notes Tables"
}
}
},
"localname": "TableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
"http://www.diffusionpharma.com/20220331/role/statement-note-8-stockbased-compensation-tables"
],
"xbrltype": "stringItemType"
},
"us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"auth_ref": [
"r117",
"r118",
"r120",
"r121",
"r122",
"r163",
"r181",
"r254",
"r296",
"r297",
"r298",
"r299",
"r300",
"r301",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r309",
"r310",
"r311",
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r319",
"r320",
"r321",
"r322",
"r323",
"r324",
"r325",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371"
],
"lang": {
"en-us": {
"role": {
"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
"label": "Financial Instruments [Domain]"
}
}
},
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_USTreasurySecuritiesMember": {
"auth_ref": [
"r61",
"r190",
"r197",
"r337"
],
"lang": {
"en-us": {
"role": {
"documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
"label": "US Treasury Securities [Member]"
}
}
},
"localname": "USTreasurySecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
"http://www.diffusionpharma.com/20220331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r93",
"r94",
"r96",
"r97",
"r98",
"r99",
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-significant-accounting-policies-policies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_WarrantMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
"label": "Warrant [Member]"
}
}
},
"localname": "WarrantMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r76",
"r83"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted average shares outstanding, basic and diluted (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.diffusionpharma.com/20220331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 7
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r101": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org/topic&trid=2134479"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(aa)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "5A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
},
"r119": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "320",
"URI": "https://asc.fasb.org/topic&trid=2196928"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r141": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r146": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "12A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 4.C)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "50",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
},
"r188": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-30)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(l)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
},
"r245": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "https://asc.fasb.org/topic&trid=2228938"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "60",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29470-108402"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29502-108402"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934302&loc=d3e29515-108402"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934811&loc=d3e32049-108421"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r295": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "https://asc.fasb.org/topic&trid=2122774"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(ii)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(5)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(6)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(7)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(b)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(6))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Subparagraph": "b.",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(b)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r360": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r361": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r362": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r363": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r364": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r365": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r366": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(1)"
},
"r367": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)"
},
"r368": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(3)"
},
"r369": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(i)"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r370": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(ii)"
},
"r371": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(iii)"
},
"r372": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(7)(c))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.8)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r62": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
}
},
"version": "2.1"
}
ZIP
60
0001437749-22-012143-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001437749-22-012143-xbrl.zip
M4$L#!!0 ( /:"K%2<<9=KT P (&8 1 9&9F;BTR,#(R,#,S,2YX
M>O]P><(KM9-/=!)LMLGDI?$B:(,Y>^ZV@)3HF*E,N
M2663^_4W)"59LF6+ENC$B8T"6T=\F6=F'HZ&H[=]_SOGYY$L&Q
M\$=DC!$@8.(8#IRT1E).CMOM'S]^[/TXV(OX0WN_T^FV?[^^ZNN^K:2S'\5,
M\N=LP-. AWN"^'L/T6,[:6PK@=F F'/0:]&(I+4P)""TO#?)X041BIY2BUH;FMFM6XCM?I>OO92/+D
MC\J!J98"LI"R/\OG![,>M%7S N2=F>8^J)\:MU4F%M0O[PK-!0[1 %H$D
M]CULF\9\5[K$&Y2I1>9GWGB:\UZR)+I'1T=MW=I"6$I.![$DEQ$?GY,ACD-
M$[._8AS2(24!+.>0C F3A0ZY9HGY Y&_XC$1$^P3>R)#"$!(KV,ZGD1<(E8Z
MQR(ES>*_BGPL=>A9.$3]Y:7C/'5(A9"#[AZ(;K4M4"PDFIG_5D
M%P.3E?3\D/2/U1"4++FEDN?ZMTDHA5Z%]36?ADPKK=/NZD<#J=-(9"4U[:Y^
MU+3Q3(RP,W0^#!ECI]/4T'TN^%BNLW2 6F"'-8&K1?<#IOL/;4
MD08.@15TU.912-J,/*CDV&X1AIP71JF5>*1.==V?9G%@QB*II]+'TJ.3"67#
M*#D$!U6*<)PF>7=DB'32<(RYK^0L3RW:$QY-")<47)K+$_4$(TZ&)RV5]GII
M-O!'B =[D+>D7>8$%,_I6D\80L*K*;QTK.+ 24N L4.2:/WBZO@X7%4=&.+'
MH?;*ABH5D.&J2L$0RN@&ZS3A9%6=8(B A+B6I]0$]] !4=BM0DHJ=6[M!9$?
MZQ^P2_;@_U0^>VHM0M*LI+20&O?]KF>=71ND]@(RF"G0J>/,=L)F&_BUT^G
MIOT\D97_>W'S3JZ
M?&1R-/6LG]B(DHI($.U ,"4*S8!P1:A])X1"'VX+\'8,,\[-#@LO&GKJK*I%"GT. 8H CA%A@CX2+XR$
MF+K;,],S!0U< #WW8A;*E#A8R\O\<16%
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M@+:<-)^-?Y1533T5UIFCRXX5\[LBPD$I$3ZG1/"T:%V+345ON55V3IEM!VC
M5JAQN6712B)=,:>\ &M97=N1I5Z]RRUOZDIW1*']\@+MZD6W'9MJU<'T3MFP6A6U!NZ)V>6W=&;4A8$\5 D%&H4(9(R'_
MMI-^]=+4>D)QX.,1M%%T#,%=T++] 4(N.
M9HC9%./BH%TXK$N$I<'IU>BY')4K;CJ\K.!5A-!M)Z9=\1\+H1Z0'A.L'!)X
M6!:&,8\KRW*5Y9FTT2U/UPS2%6V;7=/PT*E6 %TG"B L"P,9NDL52++9'8EK
M7HG([6#F1KJE[EJ@.2+L@;,K*%Y^$S4W=D?3>MC7U)']5Y[T59ME"Z*VZ57YBQX1:Z,5?#
M3Q-H.T)5NC17]L "-I3:@*YWMK7%NZ)4^065"DKE"BJG4VP[3E4ZE8LXWS;!
MS^:%K)"$!R]'+3L4KAA6?HVD@F%W_>^%YEN#$9UJC#NF63YR6_J#!2PLI
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MY3_;8#2NZ-,@8DA%%N]T#XMNK.KTFM[*-,E>C#E-
M#=0I_UL(O$H5J>C33 ^9SM18E>E=.-.;<%2JJSP(*H_Z,D4MQJXQ"0G(H#P'J;4851X+Y]3T
MCI?LE<])"GN?INS&&M:]-R[H*.2B#+K(Z[:PQQO2YS094JU7KN=KZ9?IQZ&DZFM7B=*K#FKL5SVK\Q4\IT8Q 5KF3%DZQ49:)?>JO]=],M=8>'/@;-RN8]VF
M25\^\C*.R*2]'3NOXTG*"F.O1>1[MGC%DX'.S5TE[SW;VC)@-)CX[5AOW8\*
M5MAX[>+?FREJ3_M^
M+>?BF3?'5G<"Z>UXK/[=ZQ5V;S#Q>[">Y7W:M8UH._][L&7%@SFU;5@U[[NQ
MG&/R!C#G_\'4$L#
M!!0 ( /:"K%2OS\3:K < %Y7 5 9&9F;BTR,#(R,#,S,5]C86PN
M>&UL[5S?;]LV$'X?L/_!\YX9YT>[K4'2PHV3+D#:!'&R]6V@I9--5"(]DG+B
M_O4[2G+B))9$R0[- 7U)(.E(?=_Q>+P[TCKZ<)_$G1E(Q00_[N[M['8[P ,1
M,CX^[MX.27]X[2A->4ACP>&XRT7WP_N??SKZA9!/P$%2#6%G-._<3%(>
M@AR(!#I?/UY?=$AG]_?#-W]>[_?N72][^B"JV"I!['2O]_7SQ3"80$()XT8C@<&BV*'*;EZ(
M@.I,C;44.J42YHHLQ(BY911VL+=SK\(N:KW3R54G10S7$'7,_]OK\R?O#%D4
MI69 IQ,J$[H3B*1GM+][<+#7,PUZ"%Y# EP3+C20WP@- IE"2.!^"ER!(CC<
M1.@)2!*D4AK)F-$1BYEF^%2E24+EG(CH9DA(#&@=IG W:!5X7XD9#_NHS)P/W&G"R%2:QX!.+
MH$;KYLX__?P5)RC)4 5#G88(XK1XX4F.;_&^F(X@SKMJUC '&IM)(62A]C*@
M1MEJ,80US'Y+P9C;HV52R6W%!?!ATA
M<14][N)*? =L/-'%LISW0V7PPC\]74$*B5[F4TR?A*%O6K2/I$@:CX!H/_\1
MC17;/:_8MAA:6Z+[7A*U<26V# ]\9FCE[!^9'O56!0JO$(<%@BL1L] $TV2$
MPX#!)5$3 *T>(H8I2"9"DG**\\[(V<=8:W7O,G[: -"U8J,K"5/*PH5/&\!4
M**95GX>YR2F%2%;%1HT:NHXI1,JUNJ)S.HJA-J:H$':-.TV,>4&NPA.13"5,
M4+UL!N>8I"9P(93Z OHRNJ'WY83:].*6:8AVG+FD*S2A4#5!MV'^G?Z;LAF-$8GJZQ,JY9SQ
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M,Z6-NQ]CI!+P
M*V7<%EP7:JK%6B'IOD2\PI'<<@DT9M\A_!,73,3Y"3,H@_*2/U;&^I(I?#3
M2SZ^RDXEU+BLUWZ=X[*O HP&3/5I #.(Q=0L-M7^PJK-6L53\GJ'CBIL5K1T
MB2W"XJT3M%RW6@3"6Z?6P#Q]2MA6>W[1P-WZE)[5LFF^2OLT6#9AJ[!:U7T:
MM(:LW"R$?N6J 543$L7B;M-):57'GF2?]1!=I9D(Y-E>&3I]+5F B(J]M*3.=.>8]PTEE?-+# M5/
MA-3L>V:#E]& J6S($"N22%B:E))NW9/KLH'Q'E=2S!CZUH_S6P7H.LX8ISQ
M9]''N'U69=7-._"!7SX\:_"KZ, '?@_A?%M^%1W\*&N]/)%'YUD@=*I>:G-I=1_8\.K-MYP.;IN8#<&>,-P(?-
M*=IVMC7>?U,IJ2E7@ R8*C=)BR9NSUMB:@$?,78(34:(P4)5U%@M[.>YRQ9>
M6&PVLO2JSKBN.M:,O;PJ3&[:-)H'WSX=)5I/&^4)I4_GA];C:./^;-F^]9[M
M!HJ?3K:&6J018JT8T:>"=HL<4;2)1GPJ=V^.<]OXTJ=S9J^AC?_%2DH@R26;F>+W9I(KR24/C[/M^
M,LUWKV@6,Y,$%9*B"YI.=I"S).H
M,\27_3##I)NQ,+A+*A:U\FX_@C%#Q9G0\DS((5V., "O>^0]02P,$% @ ]H*L
M5-/R/BNJ+P 76 $ !4 !D9F9N+3(P,C(P,S,Q7V1E9BYX;6SM?6MSW+:R
MX/>MVO_@]7YF;-EQ8J=.[JVQ'K[:M26M)"?W[I=3$(F1L.$0$X"4->?7+P".
M9D8C @3X $&JZ]1Q["$ =C<;C48___'O#XOTU3UFG-#L]]<'/[U]_0IG,4U(
M=OO[Z^]7T>SJ\/3T]2N>HRQ!*